

1 Characterization of sequence determinants of enhancer function using natural genetic
2 variation

3

4 Marty G. Yang,^{1,2,*} Emi Ling,^{1,3,*} Christopher J. Cowley,^{1,4} Michael E. Greenberg,^{1,#} and
5 Thomas Vierbuchen^{5,6,#,‡}

6

7 ¹ Department of Neurobiology, Harvard Medical School, Boston, MA, USA

8 ² Program in Neuroscience, Harvard Medical School, Boston, MA, USA

9 ³ Present Address: Department of Genetics, Harvard Medical School, Boston, MA, USA

10 ⁴ Present Address: Laboratory of Mammalian Cell Biology and Development, Howard
11 Hughes Medical Institute, The Rockefeller University, New York, NY, USA

12 ⁵ Developmental Biology Program, Sloan Kettering Institute for Cancer Research, New
13 York,

14 NY, USA

15 ⁶ Center for Stem Cell Biology, Sloan Kettering Institute for Cancer Research, New
16 York,

17 NY, USA

18

19 * These authors contributed equally

20 # Correspondence: meg@hms.harvard.edu and vierbuct@mskcc.org

21 ‡ Lead Contact

22

23

24 **ABSTRACT**

25 Sequence variation in enhancers that control cell type-specific gene transcription
26 contributes significantly to phenotypic variation within human populations. However, it
27 remains difficult to predict precisely the effect of any given sequence variant on
28 enhancer function due to the complexity of DNA sequence motifs that determine
29 transcription factor (TF) binding to enhancers in their native genomic context. Using F₁-
30 hybrid cells derived from crosses between distantly related inbred strains of mice, we
31 identified thousands of enhancers with allele-specific TF binding and/or activity. We find
32 that genetic variants located within the central region of enhancers are most likely to
33 alter TF binding and enhancer activity. We observe that the AP-1 family of TFs
34 (Fos/Jun) are frequently required for binding of TEAD TFs and for enhancer function.
35 However, many sequence variants outside of core motifs for AP-1 and TEAD also
36 impact enhancer function, including sequences flanking core TF motifs and AP-1 half
37 sites. Taken together, these data represent one of the most comprehensive
38 assessments of allele-specific TF binding and enhancer function to date and reveal how
39 sequence changes at enhancers alter their function across evolutionary timescales.

40

41

42

43

44

45

46

47 INTRODUCTION

48 Genome sequencing efforts have uncovered large numbers of sequence variants
49 associated with phenotypic variation in complex traits in human populations. A
50 significant proportion of these genetic variants occur within the $\sim 2\text{-}3 \times 10^6$ *cis*-regulatory
51 elements (CREs) predicted across the human genome (Carroll 2008; Maurano *et al.*,
52 2012; Pickrell 2014; Li *et al.*, 2016; Boyle *et al.*, 2017). The majority of these CREs are
53 thought to be gene-distal enhancers that potentiate gene transcription in a cell type- or
54 cell state-specific manner (Keilwagen *et al.*, 2019). However, pinpointing the specific
55 sequence changes in CREs that impact expression of linked genes, and downstream
56 molecular and cellular phenotypes, remains a critical challenge in the field (Farh *et al.*,
57 2015; Nasser *et al.*, 2021; Lappalainen and MacArthur, 2021). More specifically, it is
58 difficult to reliably distinguish functional sequence variants at CREs among a large
59 excess of neutral variants. As a result, functional assays, such as plasmid-based
60 reporters, have typically been used to assess the impact of individual sequence variants
61 within enhancers. Since these experiments can be laborious to perform and subject to
62 experimental artifacts, a better method for defining sequence-to-function relationships
63 for enhancers in their endogenous genomic context could have a transformative effect
64 on our ability to identify functional sequence variants in CREs in human genomes (Klein
65 *et al.*, 2020; Levo and Segal, 2014).

66

67 Enhancers are typically bound by $\sim 4\text{-}5$ TFs that specifically recognize short
68 sequence motifs ($\sim 6\text{-}12$ nucleotides; Bilu and Barkrai, 2005; Meuleman *et al.*, 2020).
69 TFs function as adaptor proteins to recruit transcriptional regulatory complexes to

70 enhancers, leading to potentiation of transcription at associated gene promoters.
71 Enhancer activity is highly cell type-specific, and this specificity of function is encoded
72 by the type and arrangement (also known as regulatory grammar) of TF-binding motifs
73 within each enhancer (Zeitlinger 2020; Jindal and Farley 2021). Enhancers that control
74 transcription in specific cell types are often bound by combinations of TFs that occur
75 uniquely in that cellular context (Spitz and Furlong, 2012; Wei *et al.*, 2018). This
76 complicates efforts to identify generalizable features that can be used to prioritize
77 enhancer sequence variants *in silico* (Kasowski *et al.*, 2010; Ding *et al.*, 2014;
78 Tehranchi *et al.*, 2016).

79

80 Although enhancers cannot be defined by a singular set of sequence features,
81 they do exhibit stereotyped chromatin features that can be measured genome-wide,
82 such as chromatin accessibility (controlled by TF and co-factor binding), histone post-
83 translational modifications (e.g. H3K4me1/2 and H3K27ac), and bi-directional
84 transcription of short enhancer RNAs (Heintzman *et al.*, 2007; Boyle *et al.*, 2008;
85 Creighton *et al.*, 2010; Kim *et al.*, 2010; Rada-Iglesias *et al.*, 2011). These chromatin
86 signatures have been used extensively to identify millions of putative enhancers in a
87 wide range of cell types and across different stages of organismal development
88 (Kundaje *et al.*, 2015). While mapping genomic regions that function as enhancers has
89 facilitated the identification of DNA-binding motifs enriched at enhancers in different cell
90 types, these data have not proven to be sufficient to generate quantitative, predictive
91 models for TF binding and enhancer function from available databases of enhancer
92 sequences (Deplancke *et al.*, 2016).

93

94 Sequence variants that disrupt TF binding can be highly informative for
95 identifying sequences critical for the control of enhancer function in specific cell types
96 (Wittkopp and Kalay, 2011; Albert and Kruglyak, 2015; Lappalainen 2015; Pai *et al.*,
97 2015; Vierbuchen *et al.*, 2017). Our lab and others have previously used the extensive
98 genetic variation present among inbred mouse strains to conduct “mutagenesis
99 screens” of enhancer sequences in their native chromatin context (Heinz *et al.*, 2013;
100 Vierbuchen *et al.*, 2017; Wong *et al.*, 2017; van der Veecken *et al.*, 2019). By crossing
101 highly divergent inbred mouse strains to generate F₁ hybrids, it is possible to directly
102 compare the activity of two alleles of each enhancer locus within the same cellular
103 environment.

104

105 Using mouse embryonic fibroblasts (MEFs) derived from two distinct inbred
106 strains, we found that the binding of AP-1 TFs is required for chromatin accessibility and
107 activity at many active enhancers in fibroblasts (Vierbuchen *et al.*, 2017). However, we
108 also observed that many instances of allele-specific AP-1 binding cannot be readily
109 explained by sequence variants within AP-1 motif(s). These data indicated that, at many
110 enhancer loci, sequence features outside of AP-1 TF-binding sites contribute to AP-1
111 binding. In this previous study, we observed an enrichment of variants in motifs for
112 putative collaborating TFs (e.g. TEAD) at these sites, but the nature of this collaborative
113 relationship with AP-1 remained to be defined. Both AP-1 and TEAD are broadly
114 expressed and have critical roles in mediating signal-dependent transcription
115 downstream of the Ras/MAPK and Hippo/YAP/TAZ pathways, respectively. Consistent

116 with our findings, the co-occurrence of AP-1 and TEAD motifs at enhancers has also
117 been noted in a variety of human tumor cells, providing support for the idea that AP-1
118 and TEAD coordinately regulate cell fate and proliferation. Nevertheless, further
119 delineation of the sequence features that determine the binding of AP-1 and TEAD TFs
120 to enhancers, and whether the binding of one of these TFs is dependent on the other,
121 could provide insight into enhancer function across a broad range of cellular contexts
122 (Zanconato *et al.*, 2015).

123

124 In the present study, we carried out an extensive allele-specific analysis of
125 chromatin state (ATAC-seq, H3K27ac, H3K4me1/2, and H3K4me3) and TF binding
126 (Fos, Tead1, and CTCF) in F₁-hybrid MEFs derived from crosses between C57BL/6J
127 mice and a panel of nine inbred mouse lines, including several wild-derived inbred
128 strains from distinct sub-species of mice that contain a high frequency of SNPs/indels (1
129 in every ~85-170 bp) compared to C57BL/6J mice. Using these genetically divergent
130 strains, we examined the frequency and distribution of SNPs/indels at thousands of
131 enhancers with allele-specific chromatin features and/or TF binding patterns. We found
132 that sequence variants within the central ~50 bp of enhancer sequences were most
133 likely to lead to an allele-specific change in enhancer activity. These data also revealed
134 that AP-1 binding is often required for TEAD TF binding to enhancers, whereas TEAD is
135 generally not required for AP-1 TF binding. This result is consistent with a model in
136 which AP-1 TFs function as pioneer factors to facilitate binding of additional TFs and to
137 enable enhancer selection in fibroblasts. An analysis of our allele-specific data revealed
138 that additional sequence features, such as partial AP-1 motifs and nucleotide

139 sequences flanking core AP-1 binding motifs, also contribute to enhancer function.
140 These findings provide new insight into how AP-1 TFs function at enhancers in
141 fibroblasts, and suggest that across other cell types, AP-1 TFs may employ similar
142 collaborative binding mechanisms at enhancers. In addition, our data provide new
143 insight into the crosstalk between Ras/MAPK and Hippo/YAP/TAZ/TEAD signal-
144 dependent gene expression and suggest that Ras/MAPK-induced AP-1 can play an
145 instructive role in determining the output of Hippo/YAP/TAZ/TEAD-dependent
146 transcriptional programs.

147

148 **RESULTS**

149

150 **Mapping TF binding and CREs in F₁-hybrid MEFs**

151 To identify genetic variants that modulate TF binding and/or chromatin state at
152 CREs, we isolated MEFs from male F₁-hybrid embryos derived from crosses between
153 C57BL/6J females and males from nine distinct inbred mouse strains, including four
154 wild-derived inbred strains (CAST/EiJ, MOLF/EiJ, PWK/PhJ, and SPRET/EiJ) that have
155 a high frequency of SNPs/indels compared to C57BL/6J mice (**Figure 1A**;
156 **Supplementary File 1**). Genome sequencing data is available for each inbred strain,
157 meaning that we can query up to ten distinct alleles at each CRE sequence for
158 differences in TF binding and/or *cis*-regulatory activity (Keane *et al.*, 2011). To identify
159 potential differences in CRE function that result from sequence variants between
160 maternal (C57BL/6J) and paternal chromosomes, we generated the following allele-
161 specific datasets from the four wild-derived inbred F₁-hybrid strains: chromatin features

162 associated with *cis*-regulatory function (ATAC-seq, H3K4me1/2, H3K4me3, and
163 H3K27ac), occupancy of TFs that bind many CREs in fibroblasts (Fos and Tead1),
164 putative insulator elements (CTCF), and gene transcription levels (chromatin-associated
165 RNA-seq; **Figure 1B-F, Figure 1 – figure supplement 1A; Supplementary File 2**).
166 For the remaining F₁-hybrid lines (129S1/SvImJ, A/J, BALB/cJ, DBA/2J, and
167 NOD/ShiLtJ), we only performed CUT&RUN for Fos and H3K27ac (**Supplementary**
168 **File 2**). H3K27ac Hi-ChIP was also performed in C57BL/6J MEFs to link active
169 enhancers to putative target genes and to other active CREs (**Supplementary File 3**).
170 All experiments were conducted under two distinct conditions: (1) MEFs that were
171 growth arrested in G₀ by serum starvation and (2) serum-starved MEFs that were re-
172 stimulated with serum for 90 minutes. These defined conditions reduce technical
173 variability between samples by synchronizing cells in the population at a specific stage
174 of the cell cycle and allow us to measure the binding of TFs that are induced by serum
175 stimulation, such as AP-1 TFs, at the peak of their activity (Vierbuchen *et al.*, 2017).

176
177 From each of the two alleles in F₁-hybrid lines, we identified putative primed
178 CREs (ATAC-seq summits that lack H3K27ac) and active CREs (ATAC-seq summits
179 overlapping H3K27ac peaks) (**Figure 1 – figure supplement 2A**). For all active CREs,
180 we classified sites as either gene-proximal (promoters) or gene-distal (putative
181 enhancers) based on their distance to the nearest annotated TSS (**Figure 1 – figure**
182 **supplement 2C**). In total, we found 76,517 unique genomic loci defined as active CREs
183 from the nine F₁ hybrids surveyed, and 50.4% of allele pairs at these sites harbor
184 SNP(s) within +/- 60 bp of the ATAC-seq summit used to define each enhancer locus.

185

186 **Identification of allele-specific CREs in F₁-hybrid MEFs**

187 In aggregate, across all nine F₁-hybrid lines, 24.4% of pairs of active enhancer
188 alleles on autosomes show a statistically significant difference in H3K27ac levels
189 between maternal (C57BL/6J) and paternal alleles (**Figure 1C, Figure 1 – figure**
190 **supplement 2B**). Among these allele-specific sites, 56.2% and 15.3% exhibit a >2-fold
191 and >4-fold difference in H3K27ac signal, respectively. To determine whether
192 differences in H3K27ac between alleles are associated with changes in transcription of
193 the gene that they regulate, we first identified high-confidence enhancer-TSS
194 interactions using H3K27ac Hi-ChIP data, and then examined whether transcription of
195 the linked gene was higher on the chromosome with the active enhancer allele. We
196 found that allele-specific enhancers are more likely to interact with genes that exhibit
197 allele-specific transcriptional differences than enhancers that have similar levels of
198 H3K27ac on each allele (14.5% and 9.1% of active enhancers with detectable H3K27ac
199 Hi-ChIP loops with an active promoter, respectively; **Figure 1 – figure supplement**
200 **2D**). This suggests that allele-specific differences in H3K27ac are indicative of
201 functional differences in the transcriptional regulatory activity of enhancers, consistent
202 with findings from previous studies (Creyghton *et al.*, 2010; Arnold *et al.*, 2013; Fulco *et*
203 *al.*, 2019).

204

205 Compared to H3K27ac levels at enhancers, levels of promoter-associated
206 histone modification H3K4me3 (3.6%) and gene-distal binding of CTCF (2.6%) are less
207 likely to exhibit significant differences between alleles (**Figure 1D-E**). These data are

208 consistent with previous studies suggesting that promoters and CTCF-binding sites are
209 more likely to be functionally conserved than enhancers when compared across groups
210 of distantly related species (Schmidt *et al.*, 2012; Villar *et al.*, 2015; Fudenberg and
211 Pollard, 2019). Furthermore, for each class of active CREs, we found that the frequency
212 of sites with allele-specific H3K27ac signal is proportional to the frequency of SNPs
213 between maternal and paternal alleles (**Supplementary File 4**). We noted that the
214 number of genes with an allele-specific skew in expression level per strain also scaled
215 with the total number of SNPs/indels relative to C57BL/6J in the given strain (**Figure 1 –**
216 **figure supplement 1B; Supplementary File 5**).

217

218 **Identification of sequence features that impact enhancer selection and activation**

219 Several mechanisms have been proposed for how TFs initially bind enhancers
220 leading to enhancer activation and the expression of genes that were previously silent.
221 It remains unclear whether TF binding is sufficient to displace histone octamers at
222 nucleosomal enhancers or if TF-mediated recruitment of additional co-regulatory
223 proteins, such as chromatin remodeling complexes, is also required (Lidor-Nili *et al.*,
224 2011; Paakinaho *et al.*, 2017; Johnson *et al.*, 2018). For instance, it is thought that
225 H3K4me1/2 deposition is indicative of enhancers that have been partially activated or
226 primed (Heintzman *et al.*, 2007). However, it is not known whether the majority of these
227 primed sites only become active later in development (i.e. subsequently gain H3K27ac;
228 Creighton *et al.*, 2010; Rada-Iglesias *et al.*, 2011; Bonn *et al.*, 2012; Bogdanovic *et al.*,
229 2012), or if they typically are fully activated in a single step (i.e. concurrently gain
230 H3K4me1/2 and H3K27ac), such as upon the binding of signal-dependent TFs or during

231 cellular differentiation (Kaikkonen *et al.*, 2013; Ostuni *et al.*, 2013). To address these
232 hypotheses, we examined our allele-specific H3K4me1 and H3K4me2 ChIP-seq
233 datasets, which contain thousands of allele pairs that have significant differences in
234 these histone modifications (**Figure 1F**). Our previous work suggested that disruption of
235 AP-1 TF binding results in the loss of histone marks associated with both primed and
236 active enhancers (Vierbuchen *et al.*, 2017), but whether this feature is generally
237 applicable for all enhancers (independent of AP-1 binding) and whether there are
238 mutations that inactivate enhancers without affecting H3K4me1/2 levels were
239 unresolved. To assess whether the priming and activation of enhancers are genetically
240 separable processes, we focused on H3K4me1/2 levels at enhancers with the greatest
241 difference in H3K27ac levels between alleles. We observed that 70.1% of enhancers in
242 the top decile of allele-specific enhancers have a significant and >2-fold concordant loss
243 of H3K4me1 on the inactive allele, compared to 0.6% of the bottom decile of allele-
244 specific enhancers (peaks with the smallest, statistically significant fold changes in
245 H3K27ac levels between alleles). Chromatin accessibility and AP-1 binding exhibit
246 similar changes to H3K4me1 at enhancers with strongly allele-specific H3K27ac
247 (**Figure 1G**). Together, these data reveal that few if any SNPs/indels cause a significant
248 loss of enhancer H3K27ac and maintain strong enrichment of H3K4me1/2 and
249 chromatin accessibility. Thus, our data is consistent with a model in which enhancer
250 priming/selection and activation are not separable steps mediated by distinct TF-binding
251 events at enhancers in MEFs.

252

253 **Contribution of *cis*- and *trans*-acting effects on enhancer activity**

254 In F₁ hybrids, both enhancer alleles are exposed to the same nucleoplasmic
255 environment, and thus observed differences between the two alleles are generally
256 considered to be caused directly by local SNPs (i.e. SNPs within the ~200 bp sequence
257 of chromatin accessibility at the CRE in question). However, each enhancer allele is
258 also located within a *cis*-regulatory unit or topologically associated domain (TAD), which
259 contains additional genetic changes outside of the enhancer itself that could potentially
260 impact TF binding or chromatin state at the enhancer in an allele-specific manner
261 (Kilpinen *et al.*, 2013; Grubert *et al.*, 2015). These “locus-scale” *cis*-acting mechanisms
262 could include: (1) sequence variants in other CREs at the same locus that interact with
263 an enhancer in 3D, (2) gains or losses in CTCF-binding sites that influence 3D
264 interactions between CREs within the *cis*-regulatory unit associated with that enhancer,
265 (3) structural variants that disrupt the organization of the locus such that the enhancer is
266 subject to different 3D interactions, and (4) variation in repeat elements (e.g. LINEs,
267 SINEs) within the locus that are not generally well annotated in genomic datasets (Ou *et*
268 *al.*, 2019). Another possible explanation for allele-specific activity of CREs is parent-of-
269 origin specific imprinting. We excluded CREs at known imprinted loci from subsequent
270 analyses due to the differing nature of this type of allele-specific transcriptional
271 regulation.

272

273 To quantify the relative impact of these *cis*-acting, locus-level mechanisms, we
274 analyzed sequencing reads from our allele-specific histone modification datasets, which
275 typically flank the functional CRE sequence and can thus be mapped to one allele or the
276 other even when there are no SNPs present in the accessible chromatin window at

277 enhancers (**Figure 2A, Figure 2 – figure supplement 1B**). We reasoned that
278 enhancers lacking SNPs/indels should only show an allelic skew in H3K27ac levels
279 when these aforementioned non-local mechanisms significantly contribute to the
280 function of those enhancers. Only 9.1% of enhancers that have no SNPs/indels in their
281 central 150 bp (centered on the ATAC-seq summit used to initially define the CRE)
282 exhibit a significant, allele-specific, >2-fold skew in H3K27ac levels on flanking
283 nucleosomes, compared to 22.1% of enhancers with SNPs/indels (**Figure 2F**). This
284 result suggests that it is relatively rare for SNPs outside the enhancer sequence itself to
285 influence the function of the enhancer in question. In addition, allele-specific 0-SNP
286 enhancers are not situated significantly closer (than H3K27ac-matched shared 0-SNP
287 enhancers) to an allele-specific CTCF peak (**Figure 2 – figure supplement 1A, 1C**),
288 suggesting that rearrangement of CTCF-dependent TAD boundaries is not a major
289 contributor to allele-specific differences in enhancer activity at these sites. However,
290 among 0-SNP enhancers, those with allele-specific H3K27ac signal were more likely to
291 be located near another allele-specific enhancer that has at least one SNP/indel
292 (median = 48,623 bp and 75,664 bp for allele-specific and shared 0-SNP enhancers,
293 respectively; **Figure 2 – figure supplement 1D**). In contrast, allele-specific and shared
294 0-SNP enhancers did not exhibit significant differences in their proximity to active CREs
295 in general (**Figure 2 – figure supplement 1E**). Consistent with these findings, we
296 observed that allele-specific 0-SNP enhancers are frequently located in enhancer
297 clusters with another allele-specific enhancer (within ~1-2 kb apart). In such cases, it is
298 difficult to rule out the possibility that the quantification of H3K27ac-marked
299 nucleosomes flanking the 0-SNP enhancer is not simply detecting diffuse signal from

300 other enhancer(s) in the cluster (**Figure 2B**). Furthermore, based on H3K27ac Hi-ChIP,
301 we rarely observed 0-SNP allele-specific enhancers connected via a long-range loop
302 (e.g. >10 kb) with another allele-specific SNP/indel-containing enhancer in the same
303 TAD. Thus, while previous studies have observed that allele-specific enhancers tend to
304 be highly interconnected with other allele-specific enhancers (Prescott *et al.*, 2015; Link
305 *et al.*, 2018), which has been interpreted to suggest that CREs within the same
306 topological domain can modulate each other's function, our data indicate that locus-
307 scale, *cis*-acting mechanisms exert limited effects on enhancer activity.

308

309 Next, we examined the extent to which *trans*-acting effects contribute to changes
310 in *cis*-regulatory function and gene expression between each of the F₁-hybrid MEF
311 lines. *Trans*-acting mechanisms should, in principle, affect each allele within the same
312 F₁ hybrid equally, but genetic variation between the distinct F₁-hybrid MEF lines could
313 confound quantitative comparisons of allele-specific enhancer function between each of
314 the F₁ hybrids. To measure inter-F₁, *trans*-acting differences, we examined chromatin
315 state and gene expression on the C57BL/6J X-chromosome, which is present across all
316 F₁-hybrid lines. Applying the same criteria that we had used for defining allele-specific
317 CREs on autosomes, we did not observe any CREs with significantly different H3K27ac
318 levels on the C57BL/6J X-chromosome between F₁ hybrids (**Figure 2 – figure**
319 **supplement 2A**). A similar analysis of chromatin-associated RNA-seq data revealed
320 that expression of a small subset of C57BL/6J X-chromosome genes differed
321 significantly between different F₁-hybrid strains. For example, 9.3% of expressed genes
322 on the C57BL/6J X-chromosome differed by >2-fold in expression between C57BL/6J x

323 CAST/EiJ and C57BL/6J x SPRET/EiJ MEFs (**Figure 2 – figure supplement 2B**). This
324 includes a number of genes critical for transcriptional regulation across the genome,
325 such as *Smarca1*, which is expressed at ~2-fold lower levels in C57BL/6J x SPRET/EiJ
326 hybrid MEFs compared to all other F₁-hybrid MEFs we surveyed). Taken together, these
327 data suggest that *trans*-acting effects have a limited impact on histone modification
328 levels at CREs and on gene transcription across these distinct F₁ hybrid strains.
329 Therefore, for some subsequent analyses, we chose to merge chromatin and TF-
330 binding data from allele pairs across different F₁-hybrid lines.

331

332 **Distribution of genetic variants that influence *cis*-regulatory function**

333 To characterize the types of variants that occur within CREs that cause changes
334 in enhancer activity, we started by examining active enhancers with the largest
335 differences in H3K27ac between alleles. We reasoned that these enhancers would
336 contain large-effect, loss-of-function mutations on one allele, which could reveal TF-
337 binding sites likely required for enhancer function. Across nine F₁-hybrid strains, we
338 identified a total of 29,185 pairs of enhancer alleles with a significant and >2-fold
339 difference in H3K27ac levels between alleles. Allele-specific enhancers have a
340 significantly higher frequency of SNPs/indels than H3K27ac signal-matched shared
341 enhancers (**Figure 2C**). Moreover, enhancers with a greater number of genetic variants
342 are more likely to show larger quantitative differences in H3K27ac levels (**Figure 2F-G**).
343 Across many mammalian species, loci comprising allele-specific enhancers in F₁-hybrid
344 MEFs exhibit slightly less evolutionary sequence conservation than those located at
345 shared enhancers (**Figure 2 – figure supplement 1F**). On the other hand, active

346 promoters and gene-distal CTCF peaks tolerate, from a functional standpoint, a greater
347 number of SNPs/indels than enhancers (**Figure 2D-E**).

348

349 We also hypothesized that the location of genetic variants within the enhancer is
350 likely to impact whether a given SNP/indel affects enhancer function. To explore this
351 further, we examined the distribution of SNPs/indels relative to the center of the
352 accessible chromatin region at pairs of enhancer alleles with allele-specific or shared
353 H3K27ac levels. This revealed an enrichment of SNPs/indels within a 150 bp window
354 centered on the ATAC-seq summit at allele-specific enhancers (**Figure 2H**). In contrast,
355 there was not a similar enrichment of SNPs/indels in allele-specific H3K4me3 peaks at
356 promoters (**Figure 2J**). We also examined enhancer loci with a single SNP/indel
357 present, since these sites can inform us about genetic variants that are sufficient to
358 block enhancer function. We found that 14.6% of 1-SNP/indel enhancers show an
359 allele-specific and >2-fold skew in H3K27ac levels, and we observed a more focal
360 enrichment directly at the central region of the enhancer (which we define as the middle
361 ~100 bp of the <200 bp accessible chromatin window) of SNPs/indels at allele-specific
362 enhancers (**Figure 2I**). Together, these data suggest that the central region is most
363 likely to harbor SNPs/indels that significantly modulate chromatin state at enhancers.

364

365 **Identification of TF-binding motifs required for enhancer activity in MEFs**

366 We next sought to determine candidate TF motifs that are required for enhancer
367 activity in MEFs. Analysis of the top decile of active MEF enhancers (based on relative
368 H3K27ac levels) in the C57BL/6J genome using the KMAC algorithm (Guo *et al.*, 2018)

369 generated an output of several k-mers (i.e. nucleotide sequences of k length) that we
370 manually matched to known binding motifs for several TF families (AP-1, TEAD, and
371 ETS; **Figure 3 – figure supplement 1A; Supplementary File 6**). For AP-1, the k-mer
372 identified by KMAC (5'-VTGACTCAB-3'; V indicates A/C/G and B indicates C/G/T)
373 includes the known core AP-1 site (known as a TRE; TGASTCA; S indicates C/G),
374 which is bound by heterodimers of Fos and Jun family TFs or homodimers of Jun family
375 members (Risse *et al.*, 1989; Eferl and Wagner, 2003). VTGACTCAB is the most
376 enriched k-mer at active fibroblast enhancers (30.8%, versus 1.6% of control
377 sequences; AUC = 0.450). AP-1 TFs bind DNA as dimers, with the basic leucine zipper
378 (bZIP) DNA-binding domain of each Fos/Jun monomer recognizing half of a palindromic
379 consensus motif. Because k-mer based motif representations make it possible to
380 capture internucleotide dependencies (that are lost in position weight matrix (PWM)
381 representations of TF-binding motifs), we were able to observe that certain flanking
382 nucleotides on either side of the TRE are strongly depleted from bound AP-1 motifs
383 relative to all occurrences genome-wide (i.e. T and A were depleted from the nucleotide
384 on the 5' and 3' ends of the AP-1/TRE motif, respectively).

385

386 KMAC also identified an enriched k-mer (5'-GGAATK-3'; K indicates G/T) that
387 matches the known core binding motif for the TEAD family of TFs (GGAAT; Farrance *et al.*, 1992) and includes an additional restricted nucleotide on the 3' end (10.9%, versus
388 0.6% of control sequences; AUC = 0.289). TEAD TFs are broadly expressed in
389 developing and adult cell types and function as transcriptional effectors of the
390

391 Hippo/YAP/TAZ signaling pathway that regulates cell growth and proliferation (Chen *et*
392 *al.*, 2010).

393

394 We observed a similar enrichment of AP-1 and TEAD k-mers at both
395 constitutively active enhancers and enhancers that control transcription of late-response
396 genes activated by serum stimulation (identified in Vierbuchen *et al.*, 2017; **Figure 3 –**
397 **figure supplement 1B**). This finding suggests that the specific dynamics of enhancer
398 activation cannot be readily distinguished by the presence or absence of these TF-
399 binding motifs alone, and suggests that the sequence features that determine whether
400 an enhancer is constitutively active or signal-responsive are more complex and remain
401 to be identified (Bevington *et al.*, 2016; Comoglio *et al.*, 2019).

402

403 Since these extended AP-1 and TEAD motifs were defined by their enrichment at
404 enhancers in the C57BL/6J genome (in comparison to GC-matched control regions), we
405 next sought to determine the impact of SNPs within these motifs on AP-1 and TEAD
406 binding at active enhancers using allele-specific TF-binding data (**Figure 3A-B**). We
407 performed a series of validations to ensure that distinct methods (ChIP-seq and
408 CUT&RUN) were providing similar quantitative information on TF-binding levels (**Figure**
409 **3 – figure supplement 2A-G**). We reasoned that an increased frequency of SNPs in
410 allele-specific enhancers would occur only at nucleotides required for sequence-
411 dependent binding of these TFs and not at neighboring regions flanking these
412 nucleotides (Maurano *et al.*, 2015). For active enhancer loci with allele-specific Fos
413 binding, an enrichment of SNPs is observed at the core AP-1 motif (**Figure 3C**; n = 263

414 allele pairs). Within the core motif, the lowest enrichment of SNPs was observed at the
415 central nucleotide, consistent with *in vitro* experiments suggesting that this nucleotide
416 does not strongly influence AP-1-binding affinity (Risse *et al.*, 1988). Recent *in vitro*
417 studies of AP-1 binding affinity to AP-1/TRE motifs suggests that the three nucleotides
418 flanking the core AP-1 motif (TGASTCA) can strongly modulate AP-1 TF binding by
419 altering the shape of the AP-1/TRE motif (Leonard and Kerppola, 1998; Rohs *et al.*,
420 2010; Yella *et al.*, 2018). Given these data, we assessed whether these flanking
421 sequences play a role in determining AP-1 binding site selection in chromatin. Our data
422 in **Figure 3C** suggests SNPs at the 5' and 3' flanking nucleotides of the AP-1/TRE motif
423 (VTGACTCAB) can affect AP-1 binding at active Fos-bound enhancers. More broadly,
424 there is an enrichment of SNPs in the three nucleotides flanking each side of the core
425 AP-1 binding site when considering all allele-specific Fos-bound sites from our data
426 (NNVTGACTCABNN; 9.9% and 5.6% at allele-specific and shared Fos peaks,
427 respectively; **Figure 3 – figure supplement 1C**). These results provide further evidence
428 that sequences immediately flanking core AP-1 motifs should be considered in future
429 assessments of AP-1 binding motif preferences.

430

431 Next, we found that an additional nucleotide beyond the core TEAD-binding site
432 (GGAAT) was restricted to G/T in the KMAC output (GGAATK), and SNPs were
433 enriched at all positions within this motif at allele-specific Tead1-bound enhancers
434 (**Figure 3D**). For allele-specific CTCF sites with >2-fold difference in signal, we found a
435 ~14 bp window of enriched SNPs (i.e. broader than typical DNA-binding TFs, like AP-1
436 or TEAD) that disrupt CTCF binding (**Figure 3E**), closely mirroring the ~15-20 bp

437 sequence that CTCF is predicted to bind *in vivo* (Kim *et al.*, 2007). These data indicate
438 that AP-1 and TEAD motifs are the most enriched TF motifs within active enhancers in
439 fibroblasts and functionally validate the importance of motif-flanking nucleotides for TF
440 binding in the native chromatin context.

441

442 We next sought to use our allele-specific TF-binding data to perform a targeted
443 analysis of how an allele-specific loss in AP-1 or TEAD occupancy impacts enhancer
444 chromatin state. We separately identified a set of active enhancers that have a single
445 instance of their core motifs (TGAACA or GGAAT) and have a SNP/indel that alters
446 this binding motif into a sequence not predicted to bind AP-1 or TEAD based on *in vitro*
447 binding experiments, respectively. For both classes of TFs, motif-disrupting SNPs are
448 correlated with a marked loss of binding of their cognate TFs, as expected, but this
449 incomplete loss (in aggregate) also suggests that SNPs within core motifs alone are not
450 completely predictive of changes in AP-1 or TEAD binding (**Figure 3F, 3J**). Loss of AP-
451 1 binding is associated with a substantial decrease in chromatin accessibility,
452 H3K4me1/2, and H3K27ac levels on the allele with the mutated AP-1 site (**Figure 3G-I**),
453 consistent with our previous observations from a smaller set of enhancers (Vierbuchen
454 *et al.*, 2017). This finding suggests that at enhancers that contain a single consensus
455 AP-1 site and are bound by Fos/Jun, a variant that changes a nucleotide in the core AP-
456 1 motif is likely to result in a complete loss of enhancer function, consistent with data
457 from a smaller set of plasmid-based reporters that suggest AP-1 motifs are required for
458 transcriptional activation (Malik *et al.*, 2014; Liu *et al.*, 2016). Similar analysis of Tead1-
459 bound enhancers revealed a more modest decrease in ATAC-seq, H3K4me1/2, and

460 H3K27ac signal associated with the allele lacking a predicted TEAD motif (**Figure 3K-**
461 **M**), suggesting that loss in TEAD occupancy has less severe consequences on
462 enhancer function than loss of AP-1 binding. Nevertheless, these data suggest that both
463 AP-1 and TEAD motifs play a central role in enhancer function in fibroblasts.

464

465 **AP-1 TFs facilitate binding of TEAD TFs to enhancers**

466 Although SNPs that disrupt core TF-binding motifs (AP-1, TEAD, and ETS) are
467 enriched at enhancers with allele-specific TF binding, our data also indicate that SNPs
468 in these motifs are not sufficient to explain all instances of functional variation between
469 enhancer alleles. For example, among all enhancers in the top decile of allele-specific
470 H3K27ac signal, only 13.3% had a SNP/indel overlapping a core AP-1, TEAD, and/or
471 ETS motif in their central region. In contrast, we found that 21.5% of allele-specific
472 CTCF binding sites (with >2-fold difference in CTCF signal) that contain a CTCF motif
473 (identified using position weight matrix match) had at least one SNP/indel overlapping
474 the CTCF binding site. These data favor a model in which other types of SNPs outside
475 core TF-binding motifs can collectively modulate enhancer activity.

476

477 In previous work, we found that strain-specific instances of AP-1 TF binding in
478 MEFs (in a comparison of two inbred mouse strains) that lack a mutation in a core AP-1
479 site were enriched for SNPs in TEAD motifs, suggesting a model in which AP-1 binding
480 was dependent, at least in part, on the presence of TEAD binding sites (Vierbuchen *et*
481 *al.*, 2017). However, we lacked TEAD binding data, which prevented us from examining
482 in depth the sequence determinants and functional relationship of AP-1 and TEAD

483 binding at enhancers across the genome. Other data have suggested that AP-1 and
484 TEAD TFs coordinately regulate transcriptional programs critical for cell growth and
485 proliferation during normal development and in the context of cancer (Liu *et al.*, 2016;
486 Zanconato *et al.* 2018; Park *et al.*, 2020; He *et al.*, 2021). Since multiple AP-1 and
487 TEAD TFs are also often co-expressed in the same cell types and can play functionally
488 redundant roles with one another (Seo *et al.*, 2021), it has been difficult to examine how
489 these two TFs that exhibit extensive co-occupancy work together at enhancers to
490 regulate gene transcription. With our newly generated AP-1 and TEAD binding data
491 across four wild-derived inbred F₁-hybrid lines, we could more systematically examine a
492 larger number of loci to define the functional relationship between AP-1 and TEAD.

493

494 We first quantified how often consensus TF motifs are mutated at allele-specific
495 versus shared AP-1 and TEAD peaks. If the binding of a given TF was entirely
496 dependent on the occupancy of another TF, we would expect to observe a similar loss
497 in binding of the dependent TF, regardless of which TF motif was mutated. For these
498 analyses, we included all distal Fos and Tead1 peaks in our dataset, including those
499 that do not co-occur with H3K27ac. We observed that AP-1 motif mutations are
500 frequently associated with a loss of TEAD binding, whereas AP-1 binding is more
501 weakly affected by TEAD motif mutations (**Figure 4A-B**). Strikingly, AP-1 motif
502 mutations were as enriched at allele-specific TEAD peaks as TEAD mutations were
503 (compared to sites with shared TEAD binding). Analysis of AP-1 and TEAD co-bound
504 sites (independent of whether they contained consensus AP-1 or TEAD motifs) further
505 supported a hierarchical binding relationship between these TFs. For example, 50.2%

506 (n = 821/1,635 allele pairs) of allele-specific Fos-bound sites also exhibit an allele-
507 specific loss of Tead1 binding, whereas only 8.7% (n = 821/9,416 allele pairs) of allele-
508 specific Tead1 peaks showed significant allele-specific Fos signal. In summary, these
509 data are consistent with previous studies that suggest that AP-1 can serve as a pioneer
510 TF to facilitate the binding of other TFs, such as the glucocorticoid receptor, PU.1, and
511 C/EBP (Biddie *et al.*, 2011; Heinz *et al.*, 2013), and that AP-1 binding is required for
512 inducible chromatin remodeling and nucleosome displacement at late-response gene
513 enhancers in fibroblasts (Vierbuchen *et al.*, 2017).

514

515 Data from *in vitro* studies examining TF-binding specificity have shown that TFs
516 that bind to composite motifs often prefer sequences that are distinct from their
517 consensus individual motifs (Jolma *et al.*, 2015). This led us to consider the possibility
518 that sites at which AP-1 and TEAD bind together might exhibit differential motif
519 requirements from sites where only one of these two TFs bind. We observed that AP-1-
520 only peaks contain at least one AP-1 k-mer found using KMAC (65.9%; VTGACTCAB,
521 VTGAATCAB, or VTTAGTCAY), whereas AP-1/TEAD co-bound peaks were less likely
522 to contain a consensus motif (53.8%; **Figure 4C**). Similarly, TEAD-only peaks (44.0%)
523 had a higher frequency of TEAD k-mers identified with KMAC (GGAATK) than AP-
524 1/TEAD peaks (36.0%; **Figure 4D**). These data suggest that the motif requirements for
525 AP-1/TEAD co-bound regions are slightly more flexible than sites at which only one of
526 the TFs bind.

527

528 **Identification of sequence features that determine AP-1/TEAD co-binding at**
529 **enhancers**

530 Thus far, our data suggest that many instances of AP-1 and TEAD binding
531 cannot be explained solely by mutations in consensus, core motifs for these TFs. This
532 lack of enriched TF motif mutations has been observed for other classes of TFs and in a
533 variety of model systems, suggesting that this is a general, unresolved problem in
534 genetic studies of TF binding (Deplancke *et al.*, 2016). Our dataset allowed us to
535 systematically look for recurrent features of SNPs/indels associated with allele-specific
536 AP-1 or TEAD binding outside of core motifs for these TFs. These analyses can help
537 reveal additional sequence motifs that influence AP-1 and TEAD binding, such as
538 binding sites for other TFs that bind together with AP-1 or TEAD to establish chromatin
539 accessibility. In particular, SNPs outside known TF-binding sites allow us to dissect the
540 role of motif spacing on the ability of TFs to cooperate with one another to bind
541 enhancers. Subtle changes in motif syntax have been shown to alter enhancer function
542 (Erceg *et al.*, 2014; Farley *et al.*, 2016; Shen *et al.*, 2021), and conversely, the
543 arrangement of TF-binding motifs can also be highly flexible in other contexts (Arnosti
544 and Kulkarni, 2005; Junion *et al.*, 2012; King *et al.*, 2020; Jindal and Farley, 2021).

545
546 First, we identified allele-specific gene-distal binding sites for Fos, Tead1, and
547 CTCF, and then examined the frequency of SNPs/indels (relative to the ATAC-seq peak
548 center) at these sites compared to sites with shared binding on both alleles. In **Figure**
549 **2I**, we plotted SNP/indel distributions at enhancers with allele-specific histone
550 acetylation, whereas these analyses focus instead on TF-binding sites independent of

551 H3K27ac levels. When comparing allele-specific and shared TF peaks, we found an
552 increased frequency of SNPs/indels within an ~100 bp window centered on the ATAC-
553 seq peak summit, which is similar to the pattern observed at enhancer loci with allele-
554 specific H3K27ac levels (**Figure 5A-C**).

555

556 Next, given that AP-1 motif SNPs likely contribute to the distribution observed in
557 **Figure 5A**, we repeated this analysis, but excluded allele-specific AP-1 peaks that have
558 a SNP/indel in their extended AP-1 motif (VTGACTCAB) and plotted the SNP/indel
559 frequency relative to this motif instead of the ATAC-seq peak summit. This revealed an
560 enrichment of SNPs/indels within +/- ~50 bp of the AP-1 motif (**Figure 5D**). SNPs/indels
561 were similarly distributed relative to TEAD motifs at TEAD peaks (**Figure 5E**). These
562 observed patterns of SNPs/indels are consistent with a collaborative competition model
563 for AP-1 and TEAD binding. The collaborative competition model provides an
564 explanation for how TFs gain access to enhancer sequences that form nucleosomes. In
565 this model, simultaneous binding of multiple TFs is thought to be essential to
566 outcompete high-affinity interactions of histone octamers with these enhancer DNA
567 sequences. Biophysical experiments suggest that these collaborating TFs must bind to
568 the same half of the nucleosome to compete against the histone octamer for binding
569 (i.e. the same side relative to the nucleosome dyad, <75 bp from one another; Miller and
570 Widom, 2003; Moyle-Heyrman *et al.*, 2011).

571

572 In contrast with the pattern of SNPs observed at allele-specific AP-1 and TEAD
573 peaks, when we plotted the distribution of SNPs/indels at allele-specific and shared

574 CTCF peaks, we observed a narrow enrichment of SNPs (within +/- ~10 bp) relative to
575 the CTCF motif at allele-specific compared to shared peaks (**Figure 5F**). This result
576 indicate a more restricted length scale at which genetic variants can disrupt CTCF
577 binding than those that we observed for Fos and Tead1, and suggests that CTCF
578 binding is less dependent on binding of additional, collaborating TFs.

579

580 **Contribution of partial or degenerate AP-1 motifs to AP-1 binding affinity**

581 Binding of TFs to their cognate motifs on nucleosomes is often restricted by
582 steric hindrance between TFs and histone octamers. In particular, some pioneer TFs
583 are thought to preferentially bind partial motifs over full motifs on nucleosomes (Soufi *et*
584 *al.*, 2015; Roberts *et al.*, 2021). We considered the possibility that some instances of
585 allele-specific AP-1 binding where there is an absence of a core AP-1 motif mutation
586 could be explained by SNPs in nearby partial or degenerate TF-binding motifs not
587 readily detected by traditional searches.

588

589 To examine whether binding to AP-1 half sites contributes to AP-1 recognition at
590 enhancers, we chose to examine the frequency of TGASVDB k-mers at AP-1 bound
591 sites. It should be noted that this motif is able to identify AP-1 half sites, and at the same
592 time, capture degenerate or low-affinity AP-1 motifs that are difficult to detect from
593 traditional motif searches because they bear little resemblance to predicted core motifs
594 (Kribelbauer *et al.*, 2019). Allele-specific and shared AP-1 peaks contained, on average,
595 a similar number of AP-1 half sites (in the context of TGASVDB motifs; mean = 1.17 and
596 1.20 occurrences per peak in the central 150 bp, respectively). However, we observed a

597 ~2-fold greater frequency of AP-1 half sites containing SNPs (TGASVDB) in allele-
598 specific versus shared Fos peaks (mean = 0.25 and 0.13 occurrences per peak,
599 respectively), suggesting that AP-1 half sites contribute to AP-1 TF binding in chromatin.
600 However, based on our prior analysis of mutations in full AP-1 sites, it is clear that
601 disruption of one of two half sites within an AP-1 consensus motif has a strong effect on
602 AP-1 binding in most cases, which suggests that AP-1 half sites alone might not be
603 sufficient for binding in the absence of another intact AP-1 motif at the same enhancer
604 (**Figure 3C, 3F**). Thus, we favor a model in which AP-1 half sites play an accessory role
605 in modulating levels of AP-1 occupancy, and are unlikely to be sufficient for AP-1
606 binding by themselves in the absence of a full AP-1 motif.

607

608 **Identification of k-mers predictive of AP-1 binding and/or activity using machine** 609 **learning**

610 Since core TF-binding motifs alone cannot fully distinguish TF-bound alleles from
611 those in which TFs are bound, we reasoned that additional k-mers could contribute to
612 our ability to distinguish TF-bound sites versus non-bound sites in the C57BL/6J
613 genome, and whether the identification of these k-mers might help identify other motifs
614 that are recurrently mutated in our allele-specific TF-binding data. Therefore, we applied
615 a gapped k-mer SVM approach (gkm-SVM) to our datasets that has been optimized to
616 detect k-mers of similar length to typical TF-binding motifs (Ghandi *et al.*, 2016).

617 Support vector machine (SVM) algorithms have been utilized in a variety of contexts to
618 perform classification of DNA sequences in a supervised manner (Barozzi *et al.*, 2014;
619 Ghandi *et al.*, 2016; VandenBosch *et al.*, 2022). It should be noted that k-mers identified

620 by gkm-SVM are simply DNA sequences of k length that can discriminate two sets of
621 input sequences, and do not necessarily correspond to TF-binding sites per se.

622

623 We first compared 60 bp of DNA sequences from AP-1 peaks in C57BL/6J MEFs
624 (positive set) to GC- and length-matched, randomly sampled background DNA
625 sequences from the C57BL/6J genome (negative set). The area under the receiver
626 operating characteristic curve (AUROC = 0.872) from this gkm-SVM analysis is highly
627 similar to the corresponding value obtained from a control analysis of CTCF peaks from
628 human cells, suggesting that the gkm-SVM is able to classify Fos-bound and unbound
629 regions with a low rate of detecting false positives while correctly assigning true
630 negatives. Similarly, a relatively high value for the area under the precision-recall curve
631 (AUPRC = 0.881) indicates that the gkm-SVM is able to reliably distinguish true and
632 false positives. Together, these results suggest that the information within the central 60
633 bp sequences (+/- 30 bp relative to the ATAC-seq summit) at Fos-bound peaks is
634 sufficient to train a model to reliably distinguish Fos-bound sites from control non-coding
635 regions of the same genome (**Figure 6 – figure supplement 1A**). Inclusion of
636 additional sequence beyond this central 60 bp (up to a total of 300 bp) had only a slight
637 positive effect on the performance of the model (**Figure 6A-B**). Conversely, shortening
638 of DNA sequence below 60 bp resulted in a drop-off in performance of the model. k-
639 mers containing AP-1 sites were the largest contributors to the performance of the
640 model, as expected (**Figure 6 – figure supplement 1D**). Next, to determine whether
641 sequences outside of the AP-1 motif contribute to the performance of the model, we
642 repeated this same analysis, but we computationally masked all occurrences of core

643 AP-1 sites. This revealed a slight drop in AUROC (unmasked = 0.874, masked = 0.804)
644 and AUPRC (unmasked = 0.884, masked = 0.794) values, suggesting that the model
645 retains some predictive capacity when core AP-1 motif sequences are excluded (**Figure**
646 **6A-B, Figure 6 – figure supplement 1E**).

647

648 Interestingly, k-mers containing AP-1 sites also contributed the most to model
649 performance when gkm-SVM was applied to Tead1-bound sites (**Figure 6, figure**
650 **supplement 1B, 1F**), consistent with our observations that AP-1 binding is required for
651 TEAD binding at many enhancers (**Figure 5**). When we ran the gkm-SVM on CTCF
652 peaks, we observed a highly distinct set of enriched k-mers from those found at AP-1
653 peaks. Many of these identified k-mers matched the well-documented CTCF binding
654 site, as expected (**Figure 6 – figure supplement 1C, 1G**).

655

656 We next sought to apply this gkm-SVM approach to attempt to identify k-mers
657 that distinguish between AP-1 binding sites with and without H3K27ac. Our data
658 indicate that the AP-1 binding is required for the function of many of the active
659 enhancers at which they bind in MEFs. However, AP-1 binding alone is clearly not
660 sufficient for enhancer activity. For example, 34.9% of gene-distal Fos peaks do not
661 overlap H3K27ac peaks. This suggests that the sequence features that are permissive
662 for AP-1 binding in MEFs might be separable from those that confer activity. For this
663 gkm-SVM analysis, we selected a curated set of Fos-bound allele pairs (n = 2,697) that
664 (1) have equivalent levels of Fos binding, (2) contain a consensus AP-1 site on both
665 alleles, but (3) exhibit allele-specific H3K27ac levels. We input 60 bp DNA sequences

666 (centered on the shared AP-1 consensus motif) from the active (positive set) and
667 inactive (negative set) alleles at Fos-bound enhancers (**Figure 6 – figure supplement**
668 **1H**). In contrast to the results above, the gkm-SVM failed to discriminate between these
669 two sets of sites (AUROC = 0.086 and AUPRC = 0.318), suggesting that sequence
670 features predictive of H3K27ac are more complex and cannot be readily captured by
671 this k-mer based SVM approach.

672

673 **Generalizability of sequence determinants of AP-1 binding across cell types and** 674 **species**

675 Having defined some features of sequences that determine AP-1 binding to
676 CREs in MEFs, we next extend our analyses to data derived from a larger number of
677 other cell types. To do this, we used DNase-seq footprinting data generated from a
678 large panel of human tissues and cell types (Vierstra *et al.*, 2020). These data provide
679 an unbiased view of individual TF-DNA binding interactions within CREs.

680

681 First, we identified TF footprints that overlap an extended AP-1 motif
682 (VTGACTCAB) within CREs, which we interpret as individual instances of AP-1 binding.
683 We found a total of 164,705 TF footprints (from among $>4 \times 10^6$ total footprinted
684 regions) that contain VTGACTCAB motifs. These AP-1 footprints were centrally
685 enriched within CREs (**Figure 6C**), consistent with the distribution of AP-1 k-mers
686 observed at AP-1 bound peaks in MEFs, as well as previous data examining AP-1 motif
687 frequency within human DNase-seq peaks (Grossman *et al.*, 2017). The majority of AP-
688 1 footprints were <30 bp in width (83.3%; median = 17 bp), which suggests that they

689 represent the footprint caused by binding of a single AP-1 homo/heterodimer (**Figure**
690 **6D**). CREs with AP-1 footprints typically have a total of ~3-4 additional TF footprints
691 (**Figure 6E**), and the median distance between AP-1 footprints and the nearest other TF
692 footprint is ~24 bp (**Figure 6F**). gkm-SVM analysis of sequences flanking AP-1
693 footprints (60 bp windows) revealed an enrichment of TEAD and ETS k-mers,
694 consistent with our observations at AP-1 bound sites in MEFs (**Figure 6 – figure**
695 **supplement 1I**). Together, these data suggest a model in which AP-1 is critical for CRE
696 function across many cell types and provide further insight into the nature of TF-binding
697 events that occur with AP-1 binding at CREs active across cellular contexts, such as
698 TEAD and ETS. These data will be valuable for disentangling the complex sequence
699 features that control AP-1 binding and enhancer function across diverse cell types and
700 tissues.

701

702 **DISCUSSION**

703 In this study, we leverage natural genetic variation across inbred mouse strains
704 to identify sequence variants associated with differential TF binding and/or enhancer
705 activity in their endogenous genomic context. To systematically assess the effect of
706 many genetic variants on CRE function, we mapped TF binding (AP-1, TEAD, CTCF)
707 and multiple chromatin features (ATAC-seq, H3K27ac, H3K4me1/2, H3K4me3) in up to
708 ten distinct alleles for each CRE locus. By assessing the frequency and distribution of
709 genetic variants at large numbers of CREs with shared or allele-specific TF binding
710 and/or *cis*-regulatory activity, we define features of *cis*-acting genetic variants that are
711 most predictive of differences in chromatin state and/or TF binding.

712

713 We find from our analysis of enhancer alleles with different H3K27ac levels that
714 loss of the active enhancer histone modification H3K27ac is generally not genetically
715 separable from loss of H3K4me1/2. This is interesting to consider given a number of
716 previous observations about the relative contribution of these histone modifications to
717 enhancer function: (1) we previously found that enhancers that regulate late-response
718 genes exhibit H3K4me1 enrichment in serum-starved MEFs, but have low chromatin
719 accessibility and lack H3K27ac, and upon serum-stimulation, gain H3K27 acetylation
720 and inducibly bind AP-1 TFs (Vierbuchen *et al.*, 2017), (2) recent studies suggest that
721 enhancers with H3K4me1 enrichment that lack H3K27ac are not, in fact, poised for
722 future activity, but instead that this chromatin state is a remnant of activity in a recent,
723 prior developmental stage (Kim and Shiekhattar, 2015; Jadhav *et al.*, 2019), and (3)
724 catalytic mutants of Mll3/4, enzymes responsible for H3K4me1/2 deposition, do not
725 appear to affect recruitment of RNA polymerase II to enhancers suggesting that the
726 H3K4me1/2 modification is not required for enhancer function (Dorigi *et al.*, 2017; Jang
727 *et al.*, 2017; Rickels *et al.*, 2017). Taken together, these observations suggest that in a
728 given cell type or context, H3K4me1/2-only enhancers might exhibit different *cis*-
729 regulatory features compared to enhancers that have H3K27ac enrichment because
730 they represent enhancers that were active in a previous developmental stage
731 characterized by a distinct complement of TFs expressed.

732

733 The functional sequence variants between inbred mouse strains that we
734 identified provide insight into enhancer turnover that occurs across evolution (Villar *et*

735 *al.*, 2015). We find that greater numbers of SNPs/indels at enhancers are correlated
736 with higher probabilities of allele-specific enhancer activity, and that allele-specific
737 enhancers in fibroblasts are also less conserved across species than shared
738 enhancers. Enhancers are thought to turn over rapidly because many loci contain
739 multiple enhancers with overlapping *cis*-regulatory activity, such that loss of any
740 individual single enhancer is often insufficient to cause a large change in gene
741 expression and/or result in an organismal phenotype (Osterwalder *et al.*, 2018). It would
742 also be interesting to examine how the impact of SNPs on enhancer activity correlates
743 with their frequency in natural populations or whether the SNP represents a derived or
744 ancestral state across the broader rodent lineage, as SNPs with larger impacts on
745 enhancer function would be expected to be found at lower frequencies if they are
746 potentially deleterious to overall fitness.

747

748 We also found that SNPs/indels that are associated with allele-specific H3K27ac
749 levels tend to occur within ~50 bp of the center of the accessible chromatin region used
750 to define enhancer sequences. This is further supported by enhancer loci in which
751 alleles differ by a single SNP/indel. At such enhancer alleles, these single sequence
752 variants are almost certainly causal and thus likely to explain observed differences in
753 enhancer activity. Together, these data suggest that SNPs within the central region of
754 enhancers should be prioritized in genome-wide association studies for human traits
755 and/or disease risk.

756

757 The distribution of SNPs that impact AP-1 binding to enhancers is interesting to
758 consider in the context of a recent paper that looked at sequence features that
759 distinguish AP-1 bound enhancers with high versus low activity in reporter assays
760 (Chaudhari and Cohen, 2018). Their analysis using a supervised machine learning
761 approach (gkm-SVM) suggests that most of the variation in AP-1 bound enhancer
762 activity can be predicted using input sequences that consist of the AP-1 core motif and
763 an additional +/- 10 bp on each side. The close proximity of these sequences to AP-1
764 sites contrasts with the broader window (+/- ~50 bp relative to AP-1 motifs) that we
765 observe to be important for determining AP-1 binding to chromatin in fibroblasts. More
766 generally, these observations suggest that the sequence determinants of enhancer
767 activity might be more complex within the genomic context than what has been
768 observed in reporter assays. In addition, we found that the gkm-SVM has limited ability
769 to predict activity levels of AP-1 bound sites, suggesting that deep learning approaches
770 might be required to delineate higher-order sequence features associated with active
771 enhancers in a given cellular context (Avsec *et al.*, 2021; de Almeida *et al.*, 2022).

772

773 The observed requirement for AP-1 for TEAD binding to enhancers is interesting
774 to consider given that these two distinct TFs have been previously shown to co-regulate
775 gene expression programs associated with cell proliferation and tissue growth. Both AP-
776 1 and TEAD are transcriptional effectors of intercellular signaling pathways. AP-1 TFs
777 are activated by Ras/MAPK signaling and TEAD TFs are required for the binding of the
778 transcriptional co-activators YAP and TAZ, whose nuclear localization is directly
779 regulated by Hippo signaling. Our data suggests a mechanism for crosstalk between

780 these two signaling pathways in which the transcriptional output of the Hippo pathway
781 can be modulated depending on whether Ras/MAPK is active or not. This instructive
782 function of AP-1 in selecting the enhancers at which TEAD TFs can bind is similar to the
783 role for AP-1 in facilitating the binding of transcriptional effectors from several other
784 signaling pathways, including the glucocorticoid receptor, NF- κ B, and SMAD (Biddie *et*
785 *al.*, 2011; Heinz *et al.*, 2013; Li *et al.*, 2019).

786

787 Enhancer sequences tend to be occluded by histone octamers prior to TF
788 binding, suggesting that during the process of enhancer selection some TFs must be
789 able to bind to their cognate motifs in a nucleosomal context (Tillo *et al.*, 2010; Barozzi
790 *et al.*, 2014). This complicates efforts to determine sequence features required for TF
791 binding because the affinity of a TF for nucleosomal and naked DNA often differ
792 significantly. Furthermore, different classes of TFs utilize distinct mechanisms to engage
793 with their cognate motifs on nucleosomes (Michael and Thoma, 2021). Based on *in vitro*
794 nucleosome-binding studies, bZIP TFs, which include AP-1 TFs, can only bind to their
795 cognate motifs on nucleosomes when their motifs are present on outer regions of
796 nucleosomes (i.e. furthest from predicted dyad locations; He *et al.*, 2013). These outer
797 regions are thought to be more accessible for TF binding because they are intermittently
798 unwound from the histone octamer (known as nucleosome breathing; Zhu *et al.*, 2018;
799 Zhou *et al.*, 2019). This is consistent with structural data suggesting that AP-1 TFs
800 cannot bind their full cognate motif (TGASTCA) on nucleosomes due to steric
801 constraints (Michael and Thoma, 2021). We observe an enrichment of SNPs in AP-1
802 half sites (TGASVDB) at allele-specific AP-1 peaks, raising the possibility that partial

803 AP-1 motifs contribute to AP-1 binding to nucleosomal enhancers. The binding to partial
804 motifs has been observed for other nucleosome-binding TFs, such as OCT4 (Soufi *et*
805 *al.*, 2015). Thus, we favor a model in which (1) AP-1 recognizes full motifs towards the
806 edges of nucleosomes, (2) AP-1 dimers can then bind both halves of the core AP-1 site
807 when it is accessible upon nucleosome breathing, (3) the initial binding of AP-1
808 facilitates the binding of other dependent TFs (e.g. TEAD) via collaborative competition
809 to evict the histone octamer and/or recruit co-regulatory proteins and chromatin
810 remodelers to enhancers, and (4) AP-1 might be able to bind half motifs absent
811 nucleosome breathing at any position on the nucleosome. In future, fully delineating
812 sequence requirements for AP-1 binding will require detailed *in vitro* and structural
813 experiments using naturally occurring enhancer sequences, as well as deep learning
814 approaches applied to genomic data of AP-1 binding from multiple cell types and
815 genotypes (Avsec *et al.*, 2021).

816

817 Our F₁-hybrid dataset has provided new insights into how DNA sequences within
818 CREs contribute to TF binding and enhancer function. We believe that this F₁-hybrid
819 approach for examining TF function is a powerful tool to uncover sequence
820 determinants of TF binding that cannot be easily detected from PWM-based motif
821 searches or motif enrichment analysis alone. Our F₁-hybrid datasets identify thousands
822 of enhancer allele pairs that differ subtly in their DNA sequences and yet have strongly
823 allele-specific functional properties. In the future, incorporating F₁-hybrid data from
824 additional cell types can further reveal both context-specific and broadly applicable
825 mechanisms of TF binding and enhancer activity (Halow *et al.*, 2021). More broadly, this

826 F₁-hybrid approach represents a powerful tool for understanding complex *cis*-regulatory
827 processes and can accelerate efforts to identify functional non-coding variants that
828 contribute to human disease and complex traits.

829

830 **MATERIALS AND METHODS**

831

832 **Mice**

833 All animal experiments were approved by the National Institutes of Health and the
834 Harvard Medical School Institutional Animal Care and Use Committee and were
835 conducted in compliance with the relevant ethical regulations. 6-week-old female
836 C57BL/6J mice were obtained from Jackson Labs (Bar Harbor, ME, USA) (Stock No.
837 000664) for all breeding pairs. 4- to 8-week-old male mice from the following strains
838 were also obtained from Jackson Labs: CAST/EiJ (Stock No. 000928), MOLF/EiJ (Stock
839 No. 000550), PWK/PhJ (Stock No. 003715), SPRET/EiJ (Stock No. 001146),
840 129S1/SvImJ (Stock No. 002448), A/J (Stock No. 000646), BALB/cJ (Stock No.
841 000651), DBA/2J (Stock No. 000671), NOD/ShiLtJ (Stock No. 001976). No new mouse
842 strains were generated in this study.

843

844 The study of inbred mice that are more genetically divergent from C57BL/6J in
845 combination with the use of longer sequencing reads increases the proportion of
846 informative allele-specific reads. However, higher frequencies of SNPs/indels per strain
847 results in a greater percentage of CREs with multiple genetic variants, making it difficult
848 to assign which specific SNP/indel is likely responsible for observed changes in TF

849 binding or chromatin state. Therefore, to balance these considerations, we included
850 wild-derived inbred strains with a relatively high frequency of SNPs/indels compared to
851 C57BL/6J mice (1 SNP/indel per ~85-170 bp), as well as more commonly used inbred
852 strains that are less genetically divergent from C57BL/6J mice (1 SNP/indel per ~1,000
853 bp; **Supplementary File 1**).

854

855 **Generation of MEF lines**

856 Embryos were harvested on embryonic day 13.5-14.5 and washed in room-temperature
857 PBS. The heads and internal organs were removed, and the dissected tissue was re-
858 washed in PBS. Individual embryos were placed at the center of 15-cm plates and
859 incubated for 45 min in 1 mL trypsin-EDTA 0.25% (Life Technologies 25200072).
860 Excess trypsin was carefully aspirated, and the dissected tissue was manually
861 dissociated with scissors for ~1 min. Dissociated cells were then incubated in ~1 mL
862 trypsin-EDTA at 37°C in 5% CO₂ for 30 min. Complete media was prepared by
863 supplementing DMEM (Life Technologies (Carlsbad, CA, USA) 12430062) with 10%
864 CCS (Thermo Fisher (Waltham, MA, USA) SH3008704), Penicillin-Streptomycin
865 (Thermo Fisher 15140148), MEM non-essential amino acids (Thermo Fisher
866 11140050), and 1 mM sodium pyruvate (Thermo Fisher 11360070). Trypsin was
867 quenched with 10 mL complete media, and cells were rapidly triturated up/down 10
868 times with a 10 mL serological pipette to generate a single-cell suspension. An
869 additional 10 mL complete media was added per plate, and cells were grown at 37°C in
870 5% CO₂.

871

872 When cells became fully confluent in ~2-3 days, MEFs were washed in PBS and
873 trypsinized in 3 mL trypsin-EDTA. A small aliquot of cells from each embryo were frozen
874 for genotyping (see below). Cells were pelleted by spinning at 300 g and expanded onto
875 five 15-cm plates with 20 mL complete media per plate. When fully confluent once
876 again, MEFs were trypsinized and frozen down in freeze media (50% complete media,
877 40% CCS, and 10% DMSO) in aliquots of 1 plate per cryogenic vial. Cells were placed
878 at -80°C for ~24 hr in a cell freezing container and then transferred to liquid N₂ for long-
879 term storage.

880

881 For genotyping, cells were processed with the DNeasy Blood and Tissue kit (QIAGEN
882 (Hilden, Germany) 69506). All MEF lines were tested for mycoplasma contamination with
883 the following primer pairs: 5'-CTTCWTCGACTTYCAGACCCAAGGCAT-3' (Myco2(cb))
884 with 5'-ACACCATGGGAGYTGGTAAT-3' (Myco11(cb)) and 5'-
885 GGTGTGGGTGAGTTATTACAAARTCAATT-3' (Myco5(cb)) with 5'-
886 GGAGTGAGTGGATCCATAAATTGTGA-3' (Myco6(cb)). Genotyping for the sex of each
887 MEF line was performed with the following primer pair: 5'-
888 CTGAAGCTTTTGGCTTTGAG-3' with 5'-CCACTGCCAAATTCTTTG-3'. A single 340
889 bp product was expected for female cells, and an additional 310 bp product was present
890 in male cells.

891

892 **Generation of Fos antibody**

893 We generated an in-house antibody against the full-length mouse protein for c-Fos
894 (NCBI Reference Sequence: NP_034364.1). Briefly, we purified GST-c-Fos-His as

895 detailed in Sharma *et al.*, 2019 and injected the recombinant protein into
896 immunocompromised rabbits. Serum was collected and affinity purified using a protein
897 A column before use in ChIP-seq and CUT&RUN experiments.

898

899 **Cell culture**

900 Cells were thawed onto one 15-cm plate per MEF line and grown in complete media
901 until fully confluent. For ChIP-seq and Hi-ChIP experiments, MEFs were split onto five
902 15-cm plates and grown in complete media until ~70-80% confluent. Cells were washed
903 in 10 mL room-temperature PBS and switched into 20 mL warmed starve media (0.5%
904 CCS, with the same supplement concentrations as complete media). After 26+ hours in
905 starve media, samples to be serum stimulated were incubated with 20 mL warmed
906 stimulation media (30% CCS, with the same supplement concentrations as complete
907 media) for 0, 10, or 90 min.

908

909 For ATAC-seq, RNA-seq, and CUT&RUN experiments, MEFs were thawed as above
910 and were split into 6-well dishes at a concentration of 5×10^5 cells per well in 2 mL
911 warmed starve media. Cells were grown for 26+ hours, and appropriate wells were
912 serum stimulated with 2 mL warmed stimulation media.

913

914 **Crosslinking cells**

915 Media was aspirated from MEFs, and 2 mL or 15 mL crosslinking buffer (10 mM HEPES
916 pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA) with 1% formaldehyde was added for
917 6-well or 15 cm dishes, respectively. Cells were crosslinked by shaking gently for 10

918 min at room temperature. Crosslinking was quenched by adding glycine to a final
919 concentration of 125mM and incubating for 5 min at room temperature while shaking.
920 Cells were washed once in 2 mL or 15 mL PBS for 6-well or 15 cm dishes, respectively.
921 Cells were scraped and collected in 1 mL or 5 mL cold PBS for 6-well or 15 cm dishes,
922 respectively, and pelleted by spinning at 1,000 g for 5 min at 4°C.

923

924 **ATAC-seq libraries**

925 MEFs from a 6-well dish were washed twice in 1 mL cold PBS and pelleted each time
926 by spinning at 300 g for 5 min at 4°C. 50,000 MEFs were resuspended in 50 µL cold
927 ATAC lysis buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 3 mM MgCl₂, 0.1% NP-40
928 0.1% Tween 20, 0.01% digitonin) and incubated for 3 min on ice. Lysed cells were
929 washed once in 1 mL ATAC wash buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 3 mM
930 MgCl₂, 0.1% Tween 20) by gently inverting the tube 3 times and pelleted by spinning at
931 500 g for 10 min at 4°C. Pelleted nuclei were resuspended in 50 µL transposition mix
932 (25 µL 2x TD Buffer (Illumina (San Diego, CA, USA) 20034197), 2.5 µL TDE1
933 transposase (Illumina 20034197), 0.5 µL 10% Tween 20, 0.5% 1% digitonin, 16.5 µL
934 PBS, 5 µL NF-H₂O) and incubated for 30 min at 37°C with a Thermomixer set to 1,000
935 rpm. Samples were purified with MinElute PCR Purification Kit (QIAGEN 28004) per
936 manufacturer's instructions and eluted in 13 µL NF-H₂O. Libraries were amplified by
937 adding the following to 10 µL purified DNA: 2.5 µL 25 µM Ad1 universal primer, 2.5 µL
938 25 µM Ad2.* indexing primer, 25 µL NEBNext Hi-Fi 2x PCR Master Mix (NEB (Ipswich,
939 MA, USA) M0541S), 10 µL NF-H₂O. After an initial 5 PCR cycles, libraries were
940 quantified by qPCR by adding the following to 5 µL partially amplified DNA: 0.5 µL 25

941 uM Ad1 universal primer, 0.5 μ L 25 μ M Ad2.* indexing primer, 5 μ L NEBNext Hi-Fi 2x
942 PCR Master Mix, 0.15 μ L 1x SYBR Green I (Thermo Fisher S7563), 3.85 μ L NF-H₂O.
943 All primer sequences referenced are described in Buenrostro *et al.*, 2015. The number
944 of additional PCR cycles required for amplifying remaining libraries was determined by
945 the number of qPCR cycles needed to reach 1/3 of the maximum SYBR green signal.
946 Libraries were purified with AMPure XP beads (0.5x volume; Beckman Coulter
947 (Indianapolis, IN, USA) A63881), and the supernatant was retained to remove large
948 fragments. Primer dimers were removed by a subsequent cleanup with AMPure XP
949 beads (1.3x initial volume), and libraries were eluted in 20 μ L NF-H₂O. Libraries were
950 sequenced on an Illumina NextSeq 500 with 40 bp paired-end reads.

951

952 **ChIP-seq libraries**

953 Crosslinked MEFs per protocol above from 15 cm dishes were resuspended in 1 mL L1
954 buffer (50 mM HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.25% Triton
955 X-100, 0.5% NP-40, 10% glycerol, 10 mM sodium butyrate) per 15 cm dish starting
956 material and rotated for 10 min at 4°C to lyse cells. Nuclei were pelleted by spinning at
957 1,350 g for 5 min at 4°C and resuspended in 1 mL L2 buffer (10 mM Tris-HCl pH 8.0,
958 200 mM NaCl, 10 mM sodium butyrate) per 15 cm dish starting material and rotated for
959 10 min at room temperature. Nuclei were pelleted by spinning at 1,350 g for 5 min at
960 4°C and resuspended in 300 μ L LB3 buffer (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1
961 mM EDTA, 0.5 mM EGTA, 0.1% sodium deoxycholate, 0.5% N-lauroylsarcosine, 10
962 mM sodium butyrate) per 15 cm dish starting material. Chromatin was sonicated with a
963 Bioruptor Plus (Diagenode (Denville, NJ, USA)) on “high” power setting with an “on”

964 interval of 30 sec and “off” interval of 45 sec for 36 cycles). DNA concentration was
965 determined by taking 100 μ L aliquot of sonicated chromatin, decrosslinking at 95°C for
966 15 min, and purifying with QIAquick PCR Purification Kit (QIAGEN 28104) and
967 quantifying by Nanodrop. 1 μ g of purified chromatin in 10% glycerol was run on a 2%
968 agarose gel and stained with ethidium bromide for 30 min to validate fragment size
969 (typically within ~200-1,000 bp). The remainder of the sonicated chromatin was
970 transferred to 1.5 mL tubes and centrifuged at 16,000 g for 10 min at 4°C to pellet
971 insoluble debris. Triton X-100 was added to soluble chromatin to a final 1%
972 concentration. Protein A Dynabeads (Thermo Fisher 10008D) were washed twice in 1
973 mL cold block solution (0.5% BSA (w/v), 1% Triton X-100, diluted in LB3 buffer). For
974 coupling antibodies to beads, 15 μ L bead slurry per IP were resuspended in 1.5 mL cold
975 block solution, and the appropriate amount of antibody (0.5 μ g for anti-H3K27ac (Abcam
976 (Waltham, MA, USA) ab4729), 0.5 μ g for anti-H3K4me1 (Abcam ab8895), 0.5 μ g for
977 anti-H3K4me2 (Abcam ab7766), 0.5 μ g for anti-H3K4me3 (Abcam ab8580), 2 μ g for
978 anti-Fos (in-house generated antibody and Santa Cruz Biotechnology (Dallas, TX, USA)
979 sc-7202X), 2 μ g for anti-Tead1 (Abcam ab133533), 2 μ g for anti-CTCF (Active Motif
980 (Carlsbad, CA, USA) 61312), and 2 μ g for anti-JunD (Santa Cruz Biotechnology sc74))
981 was added before rotating beads for >2 hrs at 4°C. For pre-clearing chromatin, 15 μ L
982 bead slurry was added to appropriate amount of chromatin (40 μ g for histone
983 modifications, 80 μ g for transcription factors), and additional cold LB3 buffer with 1%
984 Triton X-100 was added such that all samples had a final volume of 1.5 mL before
985 rotating samples for > 2 hrs at 4°C. Pre-cleared chromatin was added to antibody-
986 coupled beads, and additional cold LB3 buffer with 1% Triton X-100 was added such

987 that all samples had a final volume of 1.8 mL before rotating samples overnight at 4°C.
988 50 µL of pre-cleared chromatin was stored at -20°C for making input libraries. For all
989 wash steps listed below, samples were rinsed with 1 mL cold wash buffer and rotated
990 for 5 min at 4°C before separating beads with a magnet and discarding supernatant.
991 Samples were washed sequentially twice in low salt buffer (0.1% SDS, 1% Triton X-100,
992 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 150 mM NaCl), twice in high salt buffer (0.1%
993 SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 500 mM NaCl), twice in
994 LiCl buffer (250 mM LiCl, 1% NP-40, 0.5% sodium deoxycholate, 1 mM EDTA, 10 mM
995 Tris-HCl pH 8.0), and once in TE buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA).
996 Samples were eluted from beads by addition of 200 µL TE buffer with 1% SDS and
997 incubating at 65°C for 30 min, with brief vortexing every 10 min to mix. IP samples were
998 placed on magnet, and supernatant was transferred to new tubes. Input samples were
999 also thawed, and 150 µL TE buffer with 1% SDS was added. Both IP and input samples
1000 were decrosslinked by incubating at 65°C overnight. 10 µg RNase A (Sigma Aldrich (St.
1001 Louis, MO, USA) R6513) was added and samples were incubated at 37°C for 1 hr to
1002 digest RNA. 7 µL 20 µg/µL proteinase K (New England Biolabs P8107) was added, and
1003 samples were incubated at 55°C for 2 hr to digest protein. DNA was extracted with 1
1004 volume of 25:24:1 phenol-chloroform-isoamyl alcohol and purified with QIAquick PCR
1005 Purification Kit (QIAGEN 28104). Libraries were prepared with the Ovation Ultralow V2
1006 DNA-Seq Library Preparation Kit (NuGEN (Redwood City, CA, USA) 0344NB-32) per
1007 manufacturer's instructions. Libraries were sequenced on an Illumina NextSeq 500 with
1008 150 bp paired-end reads.
1009

1010 **CUT&RUN libraries**

1011 Crosslinked MEFs per protocol above from 6-well dish were washed once in 2 mL PBS
1012 and collected in 1 mL cold NE1 buffer (20 mM HEPES pH 7.5, 10 mM KCl, 1 mM MgCl₂,
1013 1 mM DTT, 0.1% Triton X-100, Roche Protease Inhibitor Cocktail (Millipore (Burlington,
1014 MA, USA) 11873580001)). Cells were permeabilized to isolate nuclei by rotating for 10
1015 min at 4°C. Nuclei were pelleted by spinning at 500 g for 5 min at 4°C and resuspended
1016 in 1 mL cold CUT&RUN wash buffer (20 mM HEPES pH 7.5, 0.2% Tween-20, 150 mM
1017 NaCl, 0.1% BSA, 0.5 mM spermidine, 10 mM sodium butyrate, Roche Protease Inhibitor
1018 Cocktail). 10 µL concanavalin-coated bead slurry (Bangs Laboratories (Fishers, IN,
1019 USA) BP531) per sample was washed twice in 1.5 mL CUT&RUN binding buffer (20
1020 mM HEPES pH 7.5, 10 mM KCl, 1 mM CaCl₂, 20 mM MnCl₂) and resuspended in a final
1021 volume of 10 µL CUT&RUN binding buffer per sample. After adding 10 µL bead slurry to
1022 each sample, tubes were inverted 10 times and incubated for 10 min at room
1023 temperature to bind nuclei. Beads were separated from wash buffer by placing on
1024 magnet for >30 sec and were resuspended in 50 µL antibody buffer (0.1% Triton X-100,
1025 2 mM EDTA, diluted in CUT&RUN wash buffer). Antibodies (in-house anti-Fos, anti-
1026 H3K27ac (Abcam ab4927), or rabbit IgG (Cell Signaling Technology (Danvers, MA,
1027 USA) 2729S)) were added at 1:50 dilution, and samples were incubated overnight at
1028 4°C. Beads were washed once in 1 mL Triton-wash buffer (0.1% Triton X-100, diluted in
1029 CUT&RUN wash buffer) and resuspended in 50 µL antibody buffer. Protein-A MNase
1030 (Skene and Henikoff, 2017) was added to a final concentration of 700 ng/mL, and
1031 samples were incubated for 1 hr at 4°C. Beads were washed twice in 1 mL Triton-wash
1032 buffer and resuspended in 100 µL Triton-wash buffer. 2 µL 100 mM CaCl₂ was added

1033 per sample to activate the MNase and each sample incubated on ice for 30 min. 100 μ L
1034 2x STOP buffer (340 mM NaCl, 20 mM EDTA, 4 mM EGTA, 0.1% Triton X-100, 50
1035 μ g/mL RNase A (Sigma Aldrich R6513), 2 pg/mL yeast spike-in DNA (provided by S.
1036 Henikoff)) was added, and samples were incubated for 20 min at 37°C to release
1037 CUT&RUN fragments from nuclei. Samples were placed on magnet, and supernatant
1038 was transferred to a new tube and added to 2 μ L 10% SDS and 2 μ L 20 mg/mL
1039 proteinase K (New England Biolabs P8107). Samples were incubated overnight at 65°C
1040 to reverse crosslinks. DNA was extracted with 1 volume of 25:24:1 phenol-chloroform-
1041 isoamyl alcohol and precipitated in 2.5 volumes of 100% ethanol with 2 μ L glycogen
1042 (Sigma Aldrich 10901393001). Pellet was washed once in 1 mL 100% ethanol and
1043 dissolved in 40 μ L 10 mM Tris-HCl pH 8.5. Libraries were prepared as described in
1044 (Skene and Henikoff, 2017), with two subsequent AMPure XP bead cleanups (1.1x
1045 volume) to fully remove contaminating adapter dimers from libraries. Libraries were
1046 sequenced on an Illumina NextSeq 500 with 40 bp paired-end reads.

1047

1048 **Hi-ChIP libraries**

1049 Hi-ChIP was performed as previously described in (Mumbach *et al.*, 2017) with the
1050 following modifications. 15 μ L of Mbol restriction enzyme (New England Biolabs R0147)
1051 was used for digesting chromatin from 15 million MEFs. Sonication was performed with
1052 a Covaris M220 with the following settings: duty cycle = 5, PIP = 70, cycles/burst = 200,
1053 and time = 8 min. 75 μ L of Protein A Dynabeads (Thermo Fisher 10008D) was used for
1054 IP and 1 μ g of anti-H3K27ac (Abcam ab4927) antibody was used per sample to typically

1055 yield 12.5 ng DNA. Accordingly, 0.6725 μ L of transposase enzyme (Nextera 20034197)
1056 was used to insert adapters, and libraries were amplified for 8 PCR cycles.

1057

1058 **RNA-seq libraries**

1059 MEFs from 15 cm dish were washed once in 15 mL cold PBS and pelleted by spinning
1060 at 300 g for 5 min at 4°C. Cell pellet was resuspended in 200 μ L cold cytoplasmic lysis
1061 buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.15% NP-40) and rotated for 5 min at
1062 4°C. Lysate was layered on top of 500 μ L cold sucrose buffer (10 mM Tris-HCl pH 7.5,
1063 150 mM NaCl, 24% sucrose (w/v)) and centrifuged at 16,000 g for 10 min at 4°C. These
1064 steps were repeated once more to achieve higher purity in the nucleoplasmic fraction.
1065 Pelleted nuclei were resuspended in 200 μ L glycerol buffer (20 mM Tris-HCl pH 7.9, 75
1066 mM NaCl, 0.5 mM EDTA, 50% glycerol, 0.85 mM DTT), and an equal volume of cold
1067 nuclear lysis buffer was added (20 mM HEPES pH 7.5, 7.5 mM MgCl₂, 0.2 mM EDTA,
1068 300 mM NaCl, 1 M urea, 1% NP-40, 1 mM DTT). Tubes were gently vortexed twice for
1069 2 sec, incubated for 1 min on ice, and centrifuged at 18,000 g for 2 min at 4°C. These
1070 steps were repeated once more to achieve higher purity in the chromatin fraction. The
1071 remaining chromatin pellet was resuspended in 50 μ L cold PBS and vortexed briefly.
1072 500 μ L of TRIzol (Thermo Fisher 15596026) was added to the pellet and vortexed for
1073 several minutes until fully resuspended. Chromatin-associated RNA was isolated with
1074 RNeasy Mini Kit (QIAGEN 74104) per manufacturer's instructions, and libraries were
1075 generated from 250 ng starting material with NEBNext Ultra Directional RNA Library
1076 Prep Kit for Illumina (New England Biolabs E7765). Libraries were sequenced on an
1077 Illumina NextSeq 500 with 150 bp paired-end reads.

1078

1079 **Pseudogenome generation**

1080 SNPs occurring in the CAST/EiJ, MOLF/EiJ, PWK/PhJ, and SPRET/EiJ genomes
1081 relative to the mm10 reference genome were obtained from SNP release version 5 of
1082 the Mouse Genomes Project (Keane *et al.*, 2011). Only high-confidence SNPs
1083 annotated with the PASS filter, filtered using VCFtools (version 0.1.12; Danecek *et al.*,
1084 2011), were used in all analyses. A separate pseudogenome for each wild-derived
1085 inbred strain was constructed from these SNPs using Modtools (version 1.0.2; Huang *et al.*,
1086 2014).

1087

1088 **Allele-specific read mapping**

1089 Reads were trimmed with the paired-end option and with SLIDINGWINDOW:5:30 using
1090 Trimmomatic (Bolger *et al.*, 2014). Paired-end reads that survived trimming were re-
1091 paired using the bbmap utility (Bushnell 2014). Both unpaired and paired reads were
1092 concurrently mapped to the C57BL/6J and appropriate pseudogenome with bowtie2
1093 using default parameters (Langmead and Salzberg, 2012). Mapped reads were
1094 converted to .bam format with samtools view (Li *et al.*, 2009) using the following options
1095 -h -b -F 3844 -q 10 and sorted by coordinate. Reads initially mapped to each
1096 pseudogenome were converted back to C57BL/6J coordinates by running Lapels
1097 (Huang *et al.*, 2014). All unpaired reads were then resorted by query name with
1098 samtools view -n and their flags were fixed with samtools fixmate. Informative reads (i.e.
1099 those that overlapped SNPs) were subsetted with the extractasReads.R utility from
1100 asSeq (Sun 2012) and remapped to the reciprocal genome using the same commands

1101 as above. To retrieve our final set of allele-specific reads, we inputted the informative
1102 reads into the WASP pipeline (van de Geijn *et al.*, 2015) to retain only those reads that
1103 map to a single locus in only one genome. Tag directories for both alleles were
1104 generated with HOMER's makeTagDirectory command with total mapped reads (i.e.
1105 before running WASP pipeline) and allele-specific reads.

1106

1107 For visualization purposes, mapped reads in .bam format were also converted to .bed
1108 format, and unique reads were retained (with sort -k1,1 -k2,2n -k3,3n -u) and extended
1109 by 150 bp with bedtools slop -l 0 -r 150. All samples were normalized to a depth of 10
1110 million reads, and read coverage was calculated by bedtools genomeCoverageBed.

1111 The output .bedgraph file was then converted with UCSC's bedGraphToBigWig utility,
1112 and all tracks displayed were visualized with the UCSC Genome Browser
1113 (GRCm38/mm10).

1114

1115 **ATAC-seq peak calling**

1116 Reads from individual bioreplicates were pooled with samtools merge. Two
1117 pseudoreplicates consisting of a random subset (50%) of total reads were generated by
1118 samtools view -h -b -s 1.5 and samtools view -h -b -s 2.5. Peaks were called from
1119 pooled reads and from two pseudoreplicates using macs2 (Liu 2014) with the following
1120 options: -p 1e-1 --nomodel --extsize 200. Peaks were also called using spp
1121 (Kharchenko *et al.*, 2008) with -npeak=500000 to include a large set of putative peaks.
1122 For both macs2 and spp, reads from input DNA pooled from all ChIP-seq experiments
1123 were used as the control sample. To analyze consistency of peak calling across

1124 pseudoreplicates, we employed an Irreproducible Discovery Rate (IDR) approach
1125 (Landt *et al.*, 2012) by running batch-consistency-analysis.R and ranking peaks by
1126 p.value for macs2 and signal.value for spp. Peaks with a global IDR score of 0.0025 or
1127 less were retained for downstream analyses. Since peaks called across samples from
1128 different genotypes can vary somewhat in their specific coordinates, we generated a
1129 total universe of possible ATAC-seq peaks by combining all sequencing reads into a
1130 single tag directory in HOMER (Heinz *et al.*, 2010). We then used the HOMER function
1131 getPeakTags with the -center option to generate single bp coordinates with maximal
1132 ATAC-seq signal (which we refer to in our manuscript as ATAC-seq summits).

1133

1134 **Allele-specific CUT&RUN peak calling**

1135 Peak calling was performed as detailed above for ATAC-seq data, except reads
1136 mapping to the C57BL/6J and corresponding pseudogenome for each F₁-hybrid line
1137 were inputted separately into macs2 and spp. CUT&RUN peaks were then intersected
1138 with all ATAC summits detected across all genotypes and were recentered on the
1139 summit of ATAC-seq signal. This was important to do because peak calling algorithms
1140 that we used would often identify multiple histone modification peaks for individual
1141 CREs due to the non-continuous enrichment in signal. This also enabled us to generate
1142 uniform windows centered around ATAC-seq summits to consistently quantify signal for
1143 CUT&RUN data across different ATAC-seq summits. Peaks from both the C57BL/6J
1144 and pseudogenome were concatenated, and only peaks with at least one SNP/indel
1145 within +/- 60 bp of the ATAC summit were retained for allele-specific analysis (as highly
1146 “mappable” sites). To determine whether the CUT&RUN signal is significantly skewed

1147 towards one allele, we used HOMER (Heinz *et al.*, 2010) to annotate read coverage
1148 with -noadj -size -250,250 for AP-1 and -noadj -size -500,500 for H3K27ac. These
1149 counts were inputted in DESeq2 (Love *et al.*, 2014), and all peaks with an FDR < 0.1
1150 were considered allele-specific. Both allele-specific and shared peaks were then filtered
1151 by the following criteria: (1) when peak summits occurred within 1 kb of one another,
1152 only the summit with the highest pooled ATAC-seq signal was retained for downstream
1153 analyses, (2) peaks within the bottom quintile of pooled ATAC-seq signal per condition
1154 per F1-hybrid line were also excluded as low-signal sites, and (3) peaks that fell within
1155 100 kb of gene bodies of known imprinted genes were filtered out of our remaining
1156 dataset to rule out differences in CRE activity that result from parent-of-origin effects
1157 (Shen *et al.*, 2014).

1158

1159 **Validation of CUT&RUN experiments**

1160 Since we modified existing protocols for CUT&RUN (Skene and Henikoff, 2017) to
1161 decrease the number of cells and sequencing reads compared to those typically
1162 required for generating ChIP-seq data, we performed a series of analyses to ensure that
1163 we were still able to quantitatively measure TF binding. While other MNase-based
1164 methods have reported sequence-dependent biases that could result in preferential
1165 cutting at open chromatin regions (Chung *et al.*, 2010), we noted a similar fraction of
1166 reads in peaks from CUT&RUN and ChIP-seq when using identical antibodies (**Figure 3**
1167 **– figure supplement 2D**), suggesting that we observe a minimal open chromatin bias
1168 with our modified CUT&RUN protocol. We also noted similar levels of binding at Fos
1169 peaks with ChIP-seq using our newly generated Fos antibody in comparison with a

1170 previously available commercial antibody, and we confirmed the specificity of our
1171 antibody by comparing peaks found in our Fos-binding data with HA ChIP-seq data from
1172 wild-type C57BL/6J MEFs and C57BL/6J MEFs that express Fos-FLAG-HA (**Figure 3 –**
1173 **figure supplement 2A-C**). When we computationally separate shorter (<120 bp) from
1174 nucleosomal (>150 bp) Fos CUT&RUN reads, we found that sub-nucleosomal reads
1175 were more likely to be enriched at the core of Fos-bound enhancers, showed greater
1176 signal-to-noise relative to an IgG control antibody (**Figure 3 – figure supplement 2F**),
1177 and could be used to detect footprints containing AP-1-binding motifs (as a proxy for the
1178 detection for sequence-specific AP-1 binding; **Figure 3 – figure supplement 2G**).

1179

1180 **Motif footprinting with CUT&RUN reads**

1181 Since CUT&RUN utilizes an antibody-targeted MNase for cleaving DNA fragments at
1182 TF-bound regions, individual cut sites derived from both ends of paired-end sequencing
1183 reads can be used for higher resolution mapping of specific nucleotides bound by TFs
1184 within peaks. DNA motifs that are recurrently protected (termed “footprints”) from
1185 MNase by chromatin-associated protein binding were identified from Fos CUT&RUN
1186 experiments performed in serum-stimulated C57BL/6J MEFs. Peak calling, motif
1187 identification, and footprinting analysis were performed using CUT&RUNtools (Zhu *et*
1188 *al.*, 2019) with default parameters. Shown in **Figure 3 – figure supplement 2G** is the
1189 aggregated cut site probability within +/- 100 bp of all identified MTGAGTCA sites at Fos
1190 CUT&RUN peaks, suggesting that our Fos CUT&RUN experiments are able to detect
1191 direct binding sites for AP-1.

1192

1193 **Allele-specific ChIP-seq peak calling**

1194 Peak calling was performed as detailed above for CUT&RUN data, except we
1195 considered all ChIP-seq peaks that overlapped ATAC-seq summits. All experiments
1196 (except for CTCF ChIP-seq, which was done in cycling cells) were performed in serum-
1197 starved and restimulated MEFs (90 min) and peaks from these datasets were analyzed
1198 separately and subsequently combined for downstream analyses, with the exception of
1199 experiments that directly queried enriched motifs at stimulus-responsive enhancers
1200 (Figure 3 – figure supplement 1B). We merged peak sets across timepoints due to the
1201 similar dynamics of enhancer activity observed across a more extensive serum
1202 stimulation timecourse in MEFs, with ~83% of enhancers exhibiting similar H3K27ac
1203 signal at 0, 10, and 90 min (Vierbuchen *et al.*, 2017). Similarly, we merged our Tead1
1204 binding data across 0 min and 90 min conditions to include as many binding sites as
1205 possible for motif analyses. This was not performed for Fos because we observed zero
1206 significant Fos peaks genome-wide in serum-starved MEFs, consistent with the fact that
1207 Fos protein is virtually undetectable in serum-starved MEFs.

1208

1209 **Detection of significant Hi-ChIP interactions**

1210 H3K27ac Hi-ChIP reads were aligned with HiC-Pro (Servant *et al.*, 2015) using an
1211 Mbol-digested mm10 genome as the reference genome. Significant H3K27ac loops
1212 were determined by running hichipper (Lareau and Aryee, 2018), inputting 1 kb
1213 windows centered on all previously identified distal active enhancers from C57BL/6J
1214 MEFs (Vierbuchen *et al.*, 2017) as possible loop anchors. Only loops that were
1215 supported by at least 10 paired-end tags per replicate and had a p-value < 1e-4 from

1216 hichipper were retained from each timepoint (0m and 90m). Using these criteria, we
1217 noted similar numbers of H3K27ac Hi-ChIP loops in our dataset as those from other cell
1218 types (Mumbach *et al.*, 2017). We generated tracks for visualization by retaining the
1219 midpoint of all significant loops.

1220

1221 **Analysis of allele-specific gene expression**

1222 Reads were mapped with STAR 2.7.3 (Dobin *et al.*, 2013) with the following options to
1223 enable WASP filtering of allele-specific reads: --outSAMattributes NH HI AS nM vG vA -
1224 -waspOutputMode SAMtag. Genome-specific reads were extracted and converted into
1225 .bam format with samtools view -h -b -F 3844 -q 10. The featureCounts command from
1226 Subread (Liao *et al.*, 2013) was used to quantify the number of allele-specific reads per
1227 genome that overlapped each mm10 Refseq gene bodies. Genes with an average
1228 expression per sample < 1 were filtered out, and counts from individual genotypes and
1229 timepoints were inputted into edgeR. Genes with an FDR < 0.05 by glmQLFTest were
1230 considered allele-specific in their expression.

1231

1232 **Scatterplots for quantifying TF binding or chromatin state across alleles**

1233 Allele-specific reads are converted from .bam files into tag directories for HOMER
1234 (Heinz *et al.*, 2010). Single bp coordinates, typically from ATAC-seq summits, are
1235 annotated with separate tag directories for the C57BL/6J and pseudogenome-specific
1236 reads with the following options: mm10 -noadj -size -250,250 for TFs and mm10 -noadj
1237 -size -500,500 for histone modifications. The resulting read coverage values are log2
1238 transformed and plotted with geom_point in ggplot2 against one another.

1239

1240 **Aggregate plots for averaging TF binding or chromatin state across peaks**

1241 Allele-specific reads were prepared as described above with HOMER. ATAC-seq peak
1242 centers or TF motif k-mers were then annotated with allele-specific read tag directories
1243 with the following options: mm10 -noadj -noann -nogene -size -1000,1000 -hist 10.

1244 Individual coverage values across 10 bp bins are plotted with geom_line in ggplot2.

1245

1246 **Number and position of SNPs/indels at *cis*-regulatory elements**

1247 To determine the total number of SNPs/indels within the central 150 bp of enhancers as
1248 in **Figure 2I**, we used bedtools window -w 75 -c and centered on the ATAC-seq summit
1249 present at each putative CRE. We also mapped the positioning of SNPs/indels relative
1250 to the ATAC-seq summit by using bedtools window -w 200, and computed the
1251 difference in coordinates between the ATAC-seq summit and the closest nucleotide
1252 present in the SNP/indel. For defining the locations of putative CTCF motifs, we inputted
1253 the MA0139.1 profile from the JASPAR database into FIMO and limited the maximum
1254 stored scores to 10^6 per genome. The density of SNPs/indels at regions with significant
1255 allele-specific signal was visualized (as in **Figure 2H-J** and **Figure 5A-F**) using the
1256 geom_histogram function with default parameters (from ggplot2), after centering upon
1257 the given coordinate of interest indicated on the horizontal axis. On these same plots,
1258 we plotted the smoothed density estimates for sites with allele-specific (black trace) and
1259 shared (blue trace) using the geom_density function (from ggplot2).

1260

1261 **Mammalian conservation scores at *cis*-regulatory elements**

1262 To more directly compare allele-specific and shared CREs with similar levels of
1263 transcriptional activity, we subsampled the pool of shared CREs such that the
1264 distribution of H3K27ac levels (+/- 500 bp from ATAC-seq summit) on the active allele
1265 matched that of the allele-specific CREs. Bigwig files with phastCons scores for 60
1266 vertebrate species for each mouse mm10 chromosome were obtained from UCSC. For
1267 each CRE, we computed a phastCons score for a 150 bp window centered on the
1268 ATAC-seq summit using the bigWigAverageOverBed script from UCSC Tools (Version
1269 3.6.3).

1270

1271 **Identifying recurrent k-mer clusters at *cis*-regulatory elements with KMAC**

1272 Nucleotide sequences present at the central 60 bp of enhancers were extracted using
1273 bedtools getfasta (Quinlan and Hall, 2010). These .fasta files were inputted into KMAC
1274 (Guo *et al.*, 2018) as the positive sequences (using the appropriate --k_seqs [n]) and
1275 enriched k-mer clusters are determined relative to random GC-matched control regions
1276 of equal length from the C57BL/6J genome (using --gc -1) with the following additional
1277 options: --k_min 5 --k_max10 --k_top 10.

1278

1279 **Identifying k-mers that distinguish classes of AP-1 bound sites with gkm-SVM**

1280 Coordinates for AP-1 peaks were converted to appropriate pseudogenome coordinates
1281 with modmap (Huang *et al.*, 2014) with -f and -d options. Nucleotide sequences in .fasta
1282 format for both alleles of each locus (60 bp window) were obtained with bedtools
1283 getfasta and were concatenated across different F₁-hybrid lines. For performing the
1284 active versus inactive Fos-bound site comparison, we used the gkm-SVM package

1285 developed by Dr. Michael Beer's lab (Ghandi *et al.*, 2016) and generated the kernel
1286 matrix by inputting the active allele DNA sequence (with higher H3K27ac levels) as the
1287 positive set and the corresponding inactive allele DNA sequence as the negative set.
1288 SVM training was done with the `gkmsvm_trainCV` command using default parameters
1289 and k-mer weights were calculated for all possible 10-mers with `gkmsvm_classify`.

1290

1291 **ACKNOWLEDGEMENTS**

1292 We would like to thank members of the Greenberg Lab for their scientific advice and
1293 input throughout this project, L. Hu for assistance in generating the anti-Fos antibody
1294 used in this study, and S. Bhunia for help with data visualization. We are grateful to L.
1295 Boxer, A. Carter, C. Davis, E. Duffy, E. Griffith, and E. Li for their helpful feedback on
1296 this manuscript.

1297

1298 M.G.Y. was supported by National Institutes of Health under training grants
1299 T32EY00711030 and T32AG000222. E.L. was supported by the National Science
1300 Foundation Graduate Research Fellowship under grant numbers DGE0946799 and
1301 DGE1144152. This work was funded by the NIH (R01 NS115965 to M.E.G.).

1302

1303 **DATA AVAILABILITY**

1304 All genomic data reported in this study have been deposited in the NCBI Gene
1305 Expression Omnibus (GSE193728).

1306

1307 **DECLARATION OF INTERESTS**

1308 The authors declare no competing interests.

1309

1310 **FIGURE LEGENDS**

1311

1312 **Figure 1. Allele-specific mapping of CREs and TF binding.**

1313 **(A)** F₁-hybrid male MEFs were derived from crosses between female C57BL/6J mice
1314 and male mice from a panel of inbred mouse strains. Experiments were performed in
1315 quiescent (0 min) and serum-stimulated (90 min) MEFs from at least two independent
1316 male embryos as biological replicates for each assay. Reads were mapped to either the
1317 maternal or paternal allele to quantify chromatin state and TF binding at CREs in an
1318 allele-specific manner. For wild-derived inbred strains, ATAC-seq data was generated
1319 using MEFs from corresponding parental lines and compared with chromatin
1320 accessibility in C57BL/6J MEFs. Similarly, H3K27ac Hi-ChIP data was obtained only
1321 from starved and serum-stimulated MEFs from C57BL/6J mice. All other genomic data
1322 indicated herein were obtained using MEFs derived from male F₁-hybrid embryos. **(B)**
1323 Example genome browser track of a locus (chr5:147,587,473-147,599,697 in mm10
1324 genome) with an allele-specific enhancer (indicated in gray, on the right) in C57BL/6J x
1325 SPRET/EiJ F₁-hybrid MEFs. Normalized read densities for ATAC-seq and H3K27ac
1326 ChIP-seq for each allele are shown. **(C-F)** Scatterplots of maternal (C57BL/6J) and
1327 paternal allele-specific signal for histone modifications and CTCF binding (n = 61,288
1328 proximal H3K27ac, n = 138,662 distal H3K27ac, n = 47,485 distal CTCF, n = 46,853
1329 proximal H3K4me3, n = 127,077 distal H3K4me1, and n = 97,084 distal H3K4me2 allele
1330 pairs, respectively). Points indicated in light and dark colors represent peaks with and

1331 without a significant skew in signal between alleles, respectively (FDR < 0.1 with
1332 DESeq2). CTCF and H3K4me3 levels were less likely to show an allele-specific skew in
1333 signal, in comparison with H3K27ac levels at active enhancers (Fisher's exact test, $p <$
1334 2.2×10^{-16} for CTCF, $p < 2.2 \times 10^{-16}$ for H3K4me3). **(G)** Scatterplot of allele-specific
1335 H3K4me1, ATAC-seq, and Fos binding signal at top decile of allele-specific enhancers,
1336 comparing signal from the active and inactive alleles (defined based on relative
1337 H3K27ac levels) to one another ($n = 13,862$ allele pairs).

1338

1339 **Figure 2. Number and position of genetic variants at allele-specific CREs. (A)**

1340 Schematic depicting TF-bound enhancer with zero SNPs/indels (denoted by red X's) in
1341 the transposase-accessible CRE region (indicated in orange). Nucleosomes flanking
1342 both ends of the accessible region at active enhancers are marked by histone post-
1343 translational modifications, which are used as proxies for the transcriptional state of
1344 each enhancer. DNA sequences in these flanking regions tend to also be less
1345 conserved than sequences within enhancers themselves, thus often allowing
1346 sequencing reads to be correctly assigned to one of two genomes in F_1 -hybrid cells in
1347 the absence of SNPs/indels within enhancer sequences. **(B)** Example genome browser
1348 track of a locus (chr11:113,290,106-113,416,149
1349 (top) and chr11:113,350,775-113,356,042 (bottom) in mm10 genome) with an allele-
1350 specific 0-SNP/indel enhancer (indicated in gray, on the left) within an enhancer
1351 "cluster" in C57BL/6J x CAST/EiJ F_1 -hybrid MEFs. The 0-SNP enhancer is situated <2
1352 kb from a SNP/indel-containing enhancer (indicated in green) within the same cluster.
1353 Normalized read densities for ATAC-seq and H3K27ac ChIP-seq for each allele are

1354 shown. Tick marks indicate positions of annotated SNPs/indels that distinguish the
1355 C57BL/6J and CAST/EiJ genomes. **(C-E)** Histogram of number of SNPs/indels present
1356 within the central 150 bp of allele-specific and signal-matched, shared active enhancers,
1357 promoters, and putative insulators (mean = 2.36 and 1.57 SNPs/indels for enhancers,
1358 respectively, two-tailed unpaired t-test, $p < 2.2 \times 10^{-16}$ for enhancers; mean = 1.84 and
1359 1.09 SNPs/indels for promoters, respectively; two-tailed unpaired t-test, $p = 7.9 \times 10^{-4}$
1360 for promoters; mean = 2.95 and 2.03 SNPs/indels for insulators, respectively; two-tailed
1361 unpaired t-test, $p < 2.2 \times 10^{-16}$ for insulators). Shared enhancers were randomly
1362 subsampled such that they were signal-matched to the active allele signal from the total
1363 set of allele-specific enhancers. **(F)** Proportion of enhancers that show allele-specific
1364 and >2-fold difference in signal, plotted as a function of the number of SNPs/indels
1365 present within their central 150 bp. Shared enhancers were randomly subsampled such
1366 that they were signal-matched to the active allele signal from the total set of allele-
1367 specific enhancers. **(G)** Box and whisker plot of H3K27ac fold changes between active
1368 and inactive alleles for allele-specific enhancers and promoters, plotted as a function of
1369 the number of SNPs/indels present within their central 150 bp. **(H-J)** Frequency of
1370 SNPs/indels at positions relative to ATAC-seq summits for allele-specific (and >2-fold)
1371 versus signal-matched, shared active enhancers, 1-SNP active enhancers, and
1372 H3K4me3-marked promoters (Pearson's Chi-squared test, $p < 2.2 \times 10^{-16}$ for
1373 enhancers, $p = 5.4 \times 10^{-5}$ for 1-SNP enhancers, $p = 2.6 \times 10^{-9}$ for promoters). Mean
1374 number of SNPs within central 150 bp of enhancers: 4.468 for enhancers with allele-
1375 specific H3K27ac levels, 3.203 for signal-matched enhancers with shared H3K27ac
1376 levels.

1377

1378 **Figure 3. Sequence motifs and changes in chromatin state at allele-specific TF-**
1379 **bound sites. (A-B)** Scatterplots of maternal (C57BL/6J) and paternal allele-specific
1380 signal for AP-1 and TEAD binding (n = 85,198 distal Fos, and 75,350 distal Tead1 allele
1381 pairs, respectively). Points indicated in light and dark colors represent peaks with and
1382 without a significant skew in signal between alleles, respectively (FDR < 0.1 with
1383 DESeq2). **(C-D)** Distribution of SNPs centered on respective k-mers (denoted by
1384 dashed lines) at allele-specific, active, and gene-distal Fos and Tead1 peaks with >2-
1385 fold difference in binding signal across alleles (n = 263 and n = 1,035 allele pairs,
1386 respectively). **(E)** Distribution of SNPs centered on CTCF PWM (JASPAR matrix ID
1387 MA0139.1; denoted by dashed lines) at allele-specific, gene-distal CTCF peaks with >2-
1388 fold difference in binding signal across alleles (n = 1,663 allele pairs). **(F-I)** Aggregate
1389 plot of allele-specific Fos, ATAC-seq, H3K4me1, and H3K27ac reads centered on
1390 ATAC-seq summits at active Fos peaks. These sites have been selected because they
1391 contain a single SNP/indel-containing AP-1 site and no shared AP-1 sites within 75 bp
1392 of the ATAC-seq summit. Signal is compared between alleles with intact versus mutated
1393 core AP-1 motifs (TGASTCA; n = 1,307 allele pairs). **(J-M)** Aggregate plot of allele-
1394 specific Tead1, ATAC-seq, H3K4me1, and H3K27ac reads centered on ATAC-seq
1395 summits at active Tead1 peaks. These sites have been selected because they contain a
1396 single SNP/indel-containing TEAD site and no shared TEAD sites within 75 bp of the
1397 ATAC-seq summit. Signal is compared between alleles with intact versus mutated core
1398 TEAD motifs (GGAATK; n = 1,132 allele pairs).

1399

1400 **Figure 4. Mechanisms of hierarchical binding for AP-1 and TEAD TFs. (A)**
1401 Percentage of allele-specific (n = 1,635 allele pairs) versus shared (n = 142,778 allele
1402 pairs) gene-distal Fos peaks that contain strain-specific core AP-1 (TGASTCA; Fisher's
1403 exact test, $p < 2.2 \times 10^{-16}$) or extended TEAD (GGAATK; Fisher's exact test, $p = 2.123 \times$
1404 10^{-9}) k-mer(s) within 75 bp of their respective ATAC-seq summits. **(B)** Percentage of
1405 allele-specific (n = 9,416 allele pairs) versus shared (n = 65,934 allele pairs) gene-distal
1406 Tead1 peaks that contain strain-specific core AP-1 (TGASTCA; Fisher's exact test, $p <$
1407 2.2×10^{-16}) or extended TEAD (GGAATK; Fisher's exact test, $p < 2.2 \times 10^{-16}$) k-mer(s)
1408 within 75 bp of their respective ATAC-seq summits. **(C)** Percentage of AP-1-only (n =
1409 15,709 loci) peaks versus AP-1/TEAD co-bound peaks (n = 2,797 loci) in the C57BL/6J
1410 genome with at least one bindable AP-1 k-mer (VTGACTCB, VTGAATCAB, or
1411 VTTAGTCAY) present within 50 bp of their respective ATAC-seq summits (Fisher's
1412 exact test, $p < 2.2 \times 10^{-16}$). **(D)** Percentage of TEAD-only (n = 2,541 loci) peaks versus
1413 AP-1/TEAD co-bound peaks in the C57BL/6J genome with at least one extended TEAD
1414 k-mer (GGAATK) present within 50 bp of their respective ATAC-seq summits (Fisher's
1415 exact test, $p = 2.406 \times 10^{-9}$).

1416

1417 **Figure 5. Distribution of genetic variants that influence AP-1, TEAD, and CTCF**
1418 **binding. (A-C)** Frequency of SNPs/indels at positions relative to ATAC-seq summits at
1419 allele-specific (with >2-fold difference in signal between alleles) versus shared gene-
1420 distal Fos, Tead1, and CTCF peaks (Pearson's Chi-squared test, $p = 9.7 \times 10^{-8}$ for AP-
1421 1, $p < 2.2 \times 10^{-16}$ for TEAD, $p < 2.2 \times 10^{-16}$ for CTCF, 100 bp window centered on ATAC-
1422 seq summit in all cases). **(D-E)** Frequency of SNPs/indels at positions relative to shared

1423 VTGACTCAB and GGAATK k-mers within 75 bp of the ATAC-seq summit at allele-
1424 specific (with >2-fold difference in signal between alleles) versus shared gene-distal Fos
1425 and Tead1 peaks, respectively. Sites have been filtered to exclude any peaks that
1426 include SNPs/indels that overlap their cognate k-mers. **(F)** Frequency of SNPs/indels at
1427 positions relative to shared CTCF PWM (MA0139.1) within 75 bp of the ATAC-seq
1428 summit at allele-specific (with >2-fold difference in signal between alleles) versus
1429 shared gene-distal CTCF peaks. Sites have been filtered to exclude any peaks that
1430 include SNPs/indels at disrupt the CTCF PWM in a strain-specific manner.

1431

1432 **Figure 6. Machine learning prediction of AP-1 binding sites genome-wide. (A-B)**

1433 Area under ROC and P-R curves for gkm-SVM comparison of Fos peaks in the
1434 C57BL/6J genome (positive set) and length-matched, random genomic regions
1435 (negative set). Shown are AUC values for different lengths of input DNA sequence,
1436 ranging from 10 to 300 bp, indicated in black. The same analysis was repeated after
1437 masking all instances of core AP-1 motifs (TGASTCA; n = 4,000 randomly selected
1438 loci), indicated in green. **(C)** Frequency of consensus, human DNase footprints (from
1439 Vierstra *et al.*, 2020) containing an extended AP-1 k-mer (VTGACTCAB) at positions
1440 relative to DNase-seq summits (n = 164,705 footprints). **(D)** Width of DNase footprints
1441 that contain an extended AP-1 k-mer (VTGACTCAB). **(E)** Number of additional DNase
1442 footprints within 100 bp of DNase-seq summits at DNase peaks with a VTGACTCAB-
1443 containing footprint. **(F)** Distance between VTGACTCAB-containing footprints and
1444 nearest neighboring DNase footprint.

1445

1446 **SUPPLEMENTAL FIGURE LEGENDS**

1447

1448 **Figure 1 – figure supplement 1. (A)** Volcano plots of chromatin-associated RNA-seq
1449 read density at annotated gene bodies. Indicated on the horizontal axis is the ratio of
1450 allele-specific signal between paternal and maternal (C57BL/6J) alleles for each F₁-
1451 hybrid strain. Transcripts whose expression levels are significantly allele-specific in
1452 DEseq2 (FDR < 0.1) and edgeR (FDR < 0.05) are highlighted in blue. **(B)** (Left) Number
1453 of SNPs/indels annotated in each wild-derived inbred mouse strain, relative to the
1454 C57BL/6J genome. (Right) Number of transcripts per F₁-hybrid line with significant
1455 allele-specific expression from reads pooled across all timepoints (0, 20, and 90 min).

1456

1457 **Figure 1 – figure supplement 2. (A)** Percentage of primed CREs (ATAC-seq summits
1458 overlapping H3K4me1/2 peaks) identified in any F₁-hybrid strain that are active
1459 regulatory elements (overlap H3K27ac peaks). In total, we found n = 283,339 pairs of
1460 active CRE alleles across all F₁-hybrids in our dataset, including n = 142,898 pairs that
1461 contained SNP(s) within the central 120 bp relative to their respective ATAC-seq
1462 summits, which we considered to be highly mappable sites. **(B)** Percentage of active
1463 CREs with a significant skew in H3K27ac levels between alleles, which we denoted as
1464 allele-specific enhancers or promoters (based on distance to their nearest annotated
1465 TSS) for subsequent analyses (n = 31,627/138,622 allele pairs; FDR < 0.1 with
1466 DEseq2). **(C)** Distance to nearest annotated TSS for active CREs identified in any F₁-
1467 hybrid strain (median = 19,786 bp). CREs were considered gene-distal if they occurred
1468 >1 kb from the nearest annotated TSS (cutoff denoted by dashed line). **(D)** Percentage

1469 of active enhancers that exhibit an allele-specific skew in nascent transcription levels for
1470 putative target genes, which were identified by statistically significant H3K27ac Hi-ChIP
1471 loops formed with active promoters that overlap an annotated TSS. Allele-specific
1472 enhancers are more likely than enhancers with shared H3K27ac signal to be linked with
1473 allele-specific transcripts (n = 1,002/6,907 and n = 3,403/37,390 detectable Hi-ChIP
1474 loops for allele-specific and shared enhancers, respectively; Fisher's exact test, p = 2.2
1475 x 10⁻¹⁶).

1476

1477 **Figure 2 – figure supplement 1. (A)** Distribution of H3K27ac signal from the active
1478 allele at (1) allele-specific enhancers, (2) all shared enhancers, and (3) a randomly
1479 subsampled set of shared enhancers that were signal-matched to the active allele of
1480 allele-specific sites. **(B)** Frequency of SNPs/indels for enhancers in our dataset
1481 assigned as 0-SNP/indel enhancers, which we defined as those having no annotated
1482 genetic variants within 75 bp of the ATAC-seq summit. No notable differences in the
1483 pattern of SNPs/indels were observed between allele-specific (black trace) and shared
1484 (blue trace) 0-SNP enhancers in regions flanking the central 150 bp window that
1485 contains no genetic variants. **(C-E)** Cumulative distribution of distances to nearest
1486 allele-specific CTCF peak, nearest allele-specific CRE, and nearest active CRE. Shown
1487 is a comparison between allele-specific and signal-matched, shared enhancers, and
1488 both sets of sites contain zero SNPs/indels in their central 150 bp (Kolmogorov-
1489 Smirnov, p = 0.0142 for nearest allele-specific CTCF peak; Kolmogorov-Smirnov D =
1490 0.02788 for nearest allele-specific CTCF peak; p < 0.0001 for nearest allele-specific
1491 CRE; Kolmogorov-Smirnov D = 0.1313 for nearest allele-specific CRE; p < 0.0001 for

1492 nearest active CRE; Kolmogorov-Smirnov D = 0.05563, for nearest active CRE). **(F)**
1493 Cumulative distribution of phastCons scores for allele-specific and signal-matched,
1494 shared active enhancers and promoters (Kolmogorov-Smirnov, $p < 0.0001$ and
1495 Kolmogorov-Smirnov D = 0.1274 for enhancers; Kolmogorov-Smirnov, $p < 0.0001$ and
1496 Kolmogorov-Smirnov D = 0.1137 for promoters).

1497

1498 **Figure 2 – figure supplement 2. (A)** Scatterplot of H3K27ac CUT&RUN signal at
1499 active CREs identified on the X-chromosome of the C57BL/6J x 129/SvImJ F₁ hybrid (n
1500 = 216 peaks). Shown are pairwise comparisons of H3K27ac read densities from the
1501 C57BL/6J x 129/SvImJ line and normalized H3K27ac CUT&RUN signal from other F₁-
1502 hybrid lines. Since we set up our breeding scheme such that each F₁-hybrid MEF line
1503 was derived only from male embryos that contain a single X-chromosome inherited from
1504 their C57BL/6J mother, this enabled us to quantify chromatin state without the need for
1505 allele-specific mapping at this particular set of CREs. **(B)** Scatterplot of nascent RNA-
1506 seq read counts overlapping gene bodies of expressed transcripts on the C57BL/6J X-
1507 chromosome (with an average of at least 100 reads per F₁-hybrid line). For example,
1508 amongst 427 expressed genes on the X-chromosome, we found that n = 39 (9.3%)
1509 were expressed with >2-fold difference in signal between alleles, when comparing the
1510 C57BL/6J x CAST/EiJ and the C57BL/6J x SPRET/EiJ F₁ hybrids.

1511

1512 **Figure 3 – figure supplement 1. (A)** Top enriched k-mer clusters identified with the
1513 KMAC algorithm present in the top decile of active C57BL/6J enhancers (Guo *et al.*,
1514 2018). DNA sequence from central 60 bp of enhancer regions were compared with

1515 random GC- and length-matched regions in the C57BL/6J genome. AP-1 k-mers were
1516 present in $n = 1,410/4,579$ active enhancers and $n = 74/4,579$ control regions,
1517 respectively. TEAD k-mers were present in $n = 499/4,579$ active enhancers and $n =$
1518 $29/4,579$ control regions, respectively. **(B)** Top enriched k-mer clusters identified with
1519 the KMAC algorithm present in late-response gene enhancers in the C57BL/6J genome.
1520 Control regions used for comparison were constitutively active enhancers in the
1521 C57BL/6J genome. **(C)** Percentage of allele-specific versus shared Fos peaks that
1522 contain an extended AP-1 motif (VTGACTCAB) with a SNP in the 3 bp flanking the core
1523 motif (TGACTCA; Fisher's exact test, $p = 5.2 \times 10^{-3}$).

1524

1525 **Figure 3 – figure supplement 2. (A)** Scatterplot of Fos ChIP-seq read density at Fos
1526 peaks originally identified in C57BL/6J MEFs, comparing signal from commercial (Santa
1527 Cruz Biotechnology sc-7202X) and in-house generated Fos (1096AE) antibodies. **(B)**
1528 Scatterplot of read density at Fos peaks originally identified in C57BL/6J MEFs,
1529 comparing signal from Fos and HA ChIP-seq experiments performed in MEFs
1530 expressing an epitope-tagged form of Fos (Fos-FLAG-HA). **(C)** Scatterplot of HA ChIP-
1531 seq read density at Fos peaks originally identified in C57BL/6J MEFs, comparing signal
1532 in wild-type C57BL/6J MEFs and Fos-FLAG-HA MEFs. **(D)** Fraction of mapped reads in
1533 C57BL/6J MEFs that fall within Fos and H3K27ac peaks (500 bp and 1 kb windows,
1534 respectively). Identical antibodies were used for ChIP-seq and CUT&RUN experiments.
1535 **(E)** Fragment lengths for mappable paired-end Fos and H3K27ac CUT&RUN reads
1536 (median = 139 and 163 bp, respectively). **(F)** Aggregate plot of Fos CUT&RUN reads
1537 mapped to the C57BL/6J genome, pooled from data across five F₁-hybrid lines, and

1538 centered on ATAC-seq summits at Fos peaks originally identified in C57BL/6J MEFs.
1539 Paired-end reads are categorized based on fragment size as either sub-nucleosomal
1540 (<120 bp) or nucleosomal (>150 bp). **(G)** MNase cut site probability for Fos CUT&RUN
1541 reads defined using CUT&RUNTools (Zhu *et al.*, 2019) identifies a TF footprint centered
1542 on MTGAGTCA k-mer at Fos peaks, suggesting that our CUT&RUN data can reliably
1543 identify instances of direct AP-1 binding.

1544

1545 **Figure 6 – figure supplement 1. (A-C)** ROC and P-R curves for gkm-SVM comparison
1546 of Fos, Tead1, and CTCF peaks compared to randomly sampled regions in the
1547 C57BL/6J genome. **(D-G)** Top enriched 10-mers from gkm-SVM comparing the central
1548 60 bp from n = 4,000 randomly selected Fos (with and without masking TGASTCA k-
1549 mers), Tead1, and CTCF peaks in C57BL/6J MEFs (positive set) with n = 4,000
1550 randomly sampled 60 bp windows across the C57BL/6J genome (negative set). **(H)** Top
1551 enriched 10-mers from gkm-SVM comparing the central 60 bp from active (positive set)
1552 and inactive allele (negative set) at Fos peaks with significantly allele-specific H3K27ac
1553 levels. **(I)** Top enriched 10-mers from gkm-SVM comparing the central 60 bp from n =
1554 4,000 DNase footprints containing VTGACTCAB k-mers (positive set) and n = 4,000
1555 random gene-distal genomic windows in the human genome (hg38) centered on
1556 VTGACTCAB k-mers (negative set).

1557

1558 **SUPPLEMENTARY FILE LEGENDS**

1559

1560 **Supplementary File 1.** Total numbers of SNPs/indels per inbred mouse strain relative
1561 to the C57BL/6J reference strain. ATAC-seq peaks were considered highly mappable if
1562 they contained a SNP/indel within a 120 bp window centered on their respective ATAC-
1563 seq summits.

1564

1565 **Supplementary File 2.** Experimental condition, replicate number, number of
1566 sequencing reads, and percentage of non-duplicated reads for all genomic assays
1567 performed in this study.

1568

1569 **Supplementary File 3.** List of all significant H3K27ac Hi-ChIP loops at 0 or 90 min
1570 serum stimulation in wild-type C57BL/6J MEFs ($p < 1e-4$). Only intra-chromosomal
1571 loops with at least 10 paired-end reads connecting them per bioreplicate were retained
1572 for analysis.

1573

1574 **Supplementary File 4.** Number of allele pairs with allele-specific and shared signal for
1575 each transcription factor or histone modification surveyed in our dataset. For Fos and
1576 H3K27ac experiments, the data from ChIP-seq (wild-derived inbred strains; CAST/EiJ,
1577 MOLF/EiJ, PWK/PhJ, SPRET/EiJ) and CUT&RUN (less divergent inbred strains;
1578 129S1/SvImJ, A/J, BALB/cJ, DBA/2J, NOD/ShiLtJ) were merged in all rows designated
1579 "all strains". Only CUT&RUN peaks with a SNP/indel present within 60 bp of the ATAC-
1580 seq summit were included for allele-specific analyses for non-wild-derived (i.e. less
1581 genetically divergent) strains.

1582

1583 **Supplementary File 5.** Significant allele-specific transcripts from chromatin-associated
1584 RNA-seq data using reads pooled from 0, 20, and 90 min timepoints. Positive and
1585 negative fold-changes indicate genes expressed at higher levels on the paternal, wild-
1586 derived allele and maternal, C57BL/6J allele, respectively.

1587

1588 **Supplementary File 6.** Location, allele-specific H3K27ac values, and DNA sequences
1589 for top decile of allele-specific enhancers, with greatest fold-change in H3K27ac signal
1590 between active and inactive alleles.

1591

1592 REFERENCES

1593

1594 Albert, F. W., & Kruglyak, L. (2015). The role of regulatory variation in complex traits
1595 and disease. *Nature Reviews. Genetics*, *16*(4), 197–212.
1596 <https://doi.org/10.1038/nrg3891>

1597

1598 Arnold, C. D., Gerlach, D., Stelzer, C., Boryń, Ł. M., Rath, M., & Stark, A. (2013).
1599 Genome-wide quantitative enhancer activity maps identified by STARR-seq. *Science*
1600 (*New York, N. Y.*), *339*(6123), 1074–1077. <https://doi.org/10.1126/science.1232542>

1601

1602 Arnosti, D. N., & Kulkarni, M. M. (2005). Transcriptional enhancers: Intelligent
1603 enhanceosomes or flexible billboards?. *Journal of Cellular Biochemistry*, *94*(5), 890–
1604 898. <https://doi.org/10.1002/jcb.20352>

1605

1606 Avsec, Ž., Weilert, M., Shrikumar, A., Krueger, S., Alexandari, A., Dalal, K., Fropf, R.,
1607 McAnany, C., Gagneur, J., Kundaje, A., & Zeitlinger, J. (2021). Base-resolution models
1608 of transcription-factor binding reveal soft motif syntax. *Nature Genetics*, *53*(3), 354–366.
1609 <https://doi.org/10.1038/s41588-021-00782-6>

1610

1611 Barozzi, I., Simonatto, M., Bonifacio, S., Yang, L., Rohs, R., Ghisletti, S., & Natoli, G. (2014).
1612 Coregulation of transcription factor binding and nucleosome occupancy through DNA
1613 features of mammalian enhancers. *Molecular Cell*, *54*(5), 844–857.
1614 <https://doi.org/10.1016/j.molcel.2014.04.006>

1615

1616 Bevington, S. L., Cauchy, P., Piper, J., Bertrand, E., Lalli, N., Jarvis, R. C., Gilding, L. N., Ott,
1617 S., Bonifer, C., & Cockerill, P. N. (2016). Inducible chromatin priming is associated with the

1618 establishment of immunological memory in T cells. *The EMBO Journal*, 35(5), 515–535.
1619 <https://doi.org/10.15252/emj.201592534>
1620
1621 Biddie, S. C., John, S., Sabo, P. J., Thurman, R. E., Johnson, T. A., Schiltz, R. L., Miranda, T.
1622 B., Sung, M. H., Trump, S., Lightman, S. L., Vinson, C., Stamatoyannopoulos, J. A., & Hager,
1623 G. L. (2011). Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid
1624 receptor binding. *Molecular Cell*, 43(1), 145–155.
1625 <https://doi.org/10.1016/j.molcel.2011.06.016>
1626
1627 Bilu, Y., & Barkai, N. (2005). The design of transcription-factor binding sites is affected
1628 by combinatorial regulation. *Genome Biology*, 6(12), R103. [https://doi.org/10.1186/gb-](https://doi.org/10.1186/gb-2005-6-12-r103)
1629 [2005-6-12-r103](https://doi.org/10.1186/gb-2005-6-12-r103)
1630
1631 Bogdanovic, O., Fernandez-Miñán, A., Tena, J. J., de la Calle-Mustienes, E., Hidalgo,
1632 C., van Kruysbergen, I., van Heeringen, S. J., Veenstra, G. J., & Gómez-Skarmeta, J. L.
1633 (2012). Dynamics of enhancer chromatin signatures mark the transition from
1634 pluripotency to cell specification during embryogenesis. *Genome Research*, 22(10),
1635 2043–2053. <https://doi.org/10.1101/gr.134833.111>
1636
1637 Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: a flexible trimmer for
1638 Illumina sequence data. *Bioinformatics (Oxford, England)*, 30(15), 2114–2120.
1639 <https://doi.org/10.1093/bioinformatics/btu170>
1640
1641 Bonn, S., Zinzen, R. P., Girardot, C., Gustafson, E. H., Perez-Gonzalez, A., Delhomme,
1642 N., Ghavi-Helm, Y., Wilczyński, B., Riddell, A., & Furlong, E. E. (2012). Tissue-specific
1643 analysis of chromatin state identifies temporal signatures of enhancer activity during
1644 embryonic development. *Nature Genetics*, 44(2), 148–156.
1645 <https://doi.org/10.1038/ng.1064>
1646
1647 Boyle, A. P., Davis, S., Shulha, H. P., Meltzer, P., Margulies, E. H., Weng, Z., Furey, T.
1648 S., & Crawford, G. E. (2008). High-resolution mapping and characterization of open
1649 chromatin across the genome. *Cell*, 132(2), 311–322.
1650 <https://doi.org/10.1016/j.cell.2007.12.014>
1651
1652 Boyle, E. A., Li, Y. I., & Pritchard, J. K. (2017). An Expanded View of Complex Traits:
1653 From Polygenic to Omnigenic. *Cell*, 169(7), 1177–1186.
1654 <https://doi.org/10.1016/j.cell.2017.05.038>
1655
1656 Buenrostro, J. D., Wu, B., Chang, H. Y., & Greenleaf, W. J. (2015). ATAC-seq: A Method for
1657 Assaying Chromatin Accessibility Genome-Wide. *Current Protocols in Molecular*
1658 *Biology*, 109, 21.29.1–21.29.9. <https://doi.org/10.1002/0471142727.mb2129s109>
1659
1660 Bushnell, B. (2014). BMap: A Fast, Accurate, Splice-Aware Aligner. *Lawrence*
1661 *Berkeley National Laboratory*. LBNL Report #: LBNL-7065E. Retrieved from
1662 <https://escholarship.org/uc/item/1h3515gn>

1663
1664 Carroll S. B. (2008). Evo-devo and an expanding evolutionary synthesis: a genetic
1665 theory of morphological evolution. *Cell*, 134(1), 25–36.
1666 <https://doi.org/10.1016/j.cell.2008.06.030>
1667
1668 Chen, L., Loh, P. G., & Song, H. (2010). Structural and functional insights into the
1669 TEAD-YAP complex in the Hippo signaling pathway. *Protein & Cell*, 1(12), 1073–1083.
1670 <https://doi.org/10.1007/s13238-010-0138-3>
1671
1672 Chung, H. R., Dunkel, I., Heise, F., Linke, C., Krobitch, S., Ehrenhofer-Murray, A. E.,
1673 Sperling, S. R., & Vingron, M. (2010). The effect of micrococcal nuclease digestion on
1674 nucleosome positioning data. *PLoS One*, 5(12), e15754.
1675 <https://doi.org/10.1371/journal.pone.0015754>
1676
1677 Comoglio, F., Simonatto, M., Polletti, S., Liu, X., Smale, S. T., Barozzi, I., & Natoli, G.
1678 (2019). Dissection of acute stimulus-inducible nucleosome remodeling in mammalian
1679 cells. *Genes & Development*, 33(17-18), 1159–1174.
1680 <https://doi.org/10.1101/gad.326348.119>
1681
1682 Creighton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J.,
1683 Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., Boyer, L. A., Young, R. A., &
1684 Jaenisch, R. (2010). Histone H3K27ac separates active from poised enhancers and predicts
1685 developmental state. *Proceedings of the National Academy of Sciences of the United States of*
1686 *America*, 107(50), 21931–21936. <https://doi.org/10.1073/pnas.1016071107>
1687
1688 Danecek, P., Auton, A., Abecasis, G., Albers, C. A., Banks, E., DePristo, M. A.,
1689 Handsaker, R. E., Lunter, G., Marth, G. T., Sherry, S. T., McVean, G., Durbin, R., &
1690 1000 Genomes Project Analysis Group (2011). The variant call format and
1691 VCFtools. *Bioinformatics (Oxford, England)*, 27(15), 2156–2158.
1692 <https://doi.org/10.1093/bioinformatics/btr330>
1693
1694 de Almeida, B. P., Reiter, F., Pagani, M., & Stark, A. (2022). DeepSTARR predicts
1695 enhancer activity from DNA sequence and enables the de novo design of synthetic
1696 enhancers. *Nature Genetics*, 54(5), 613–624. [https://doi.org/10.1038/s41588-022-](https://doi.org/10.1038/s41588-022-01048-5)
1697 [01048-5](https://doi.org/10.1038/s41588-022-01048-5)
1698
1699 Deplancke, B., Alpern, D., & Gardeux, V. (2016). The Genetics of Transcription Factor
1700 DNA Binding Variation. *Cell*, 166(3), 538–554. <https://doi.org/10.1016/j.cell.2016.07.012>
1701
1702 Ding, Z., Ni, Y., Timmer, S. W., Lee, B. K., Battenhouse, A., Louzada, S., Yang, F.,
1703 Dunham, I., Crawford, G. E., Lieb, J. D., Durbin, R., Iyer, V. R., & Birney, E. (2014).
1704 Quantitative genetics of CTCF binding reveal local sequence effects and different
1705 modes of X-chromosome association. *PLoS Genetics*, 10(11), e1004798.
1706 <https://doi.org/10.1371/journal.pgen.1004798>
1707

1708 Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P.,
1709 Chaisson, M., & Gingeras, T. R. (2013). STAR: ultrafast universal RNA-seq
1710 aligner. *Bioinformatics (Oxford, England)*, *29*(1), 15–21.
1711 <https://doi.org/10.1093/bioinformatics/bts635>
1712

1713 Dorigi, K. M., Swigut, T., Henriques, T., Bhanu, N. V., Scruggs, B. S., Nady, N., Still, C.
1714 D., 2nd, Garcia, B. A., Adelman, K., & Wysocka, J. (2017). MII3 and MII4 Facilitate
1715 Enhancer RNA Synthesis and Transcription from Promoters Independently of H3K4
1716 Monomethylation. *Molecular Cell*, *66*(4), 568–576.e4.
1717 <https://doi.org/10.1016/j.molcel.2017.04.018>
1718

1719 Erceg, J., Saunders, T. E., Girardot, C., Devos, D. P., Hufnagel, L., & Furlong, E. E.
1720 (2014). Subtle changes in motif positioning cause tissue-specific effects on robustness
1721 of an enhancer's activity. *PLoS Genetics*, *10*(1), e1004060.
1722 <https://doi.org/10.1371/journal.pgen.1004060>
1723

1724 Eferl, R., & Wagner, E. F. (2003). AP-1: a double-edged sword in tumorigenesis. *Nature*
1725 *Reviews. Cancer*, *3*(11), 859–868. <https://doi.org/10.1038/nrc1209>
1726

1727 Farh, K. K., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W. J., Beik, S., Shores, N.,
1728 Whitton, H., Ryan, R. J., Shishkin, A. A., Hatan, M., Carrasco-Alfonso, M. J., Mayer, D.,
1729 Luckey, C. J., Patsopoulos, N. A., De Jager, P. L., Kuchroo, V. K., Epstein, C. B., Daly, M. J.,
1730 Hafler, D. A., ... Bernstein, B. E. (2015). Genetic and epigenetic fine mapping of causal
1731 autoimmune disease variants. *Nature*, *518*(7539), 337–343.
1732 <https://doi.org/10.1038/nature13835>
1733

1734 Farley, E. K., Olson, K. M., Zhang, W., Rokhsar, D. S., & Levine, M. S. (2016). Syntax
1735 compensates for poor binding sites to encode tissue specificity of developmental
1736 enhancers. *Proceedings of the National Academy of Sciences of the United States of*
1737 *America*, *113*(23), 6508–6513. <https://doi.org/10.1073/pnas.1605085113>
1738

1739 Farrance, I. K., Mar, J. H., & Ordahl, C. P. (1992). M-CAT binding factor is related to the
1740 SV40 enhancer binding factor, TEF-1. *The Journal of Biological Chemistry*, *267*(24),
1741 17234–17240.
1742

1743 Fudenberg, G., & Pollard, K. S. (2019). Chromatin features constrain structural variation
1744 across evolutionary timescales. *Proceedings of the National Academy of Sciences of the*
1745 *United States of America*, *116*(6), 2175–2180. <https://doi.org/10.1073/pnas.1808631116>
1746

1747 Fulco, C. P., Nasser, J., Jones, T. R., Munson, G., Bergman, D. T., Subramanian, V., Grossman,
1748 S. R., Anyoha, R., Doughty, B. R., Patwardhan, T. A., Nguyen, T. H., Kane, M., Perez, E. M.,
1749 Durand, N. C., Lareau, C. A., Stamenova, E. K., Aiden, E. L., Lander, E. S., & Engreitz, J. M.
1750 (2019). Activity-by-contact model of enhancer-promoter regulation from thousands of

1751 CRISPR perturbations. *Nature Genetics*, 51(12), 1664–1669. [https://doi.org/10.1038/s41588-](https://doi.org/10.1038/s41588-019-0538-0)
1752 019-0538-0
1753
1754 Ghandi, M., Mohammad-Noori, M., Ghareghani, N., Lee, D., Garraway, L., & Beer, M.
1755 A. (2016). gkmSVM: an R package for gapped-kmer SVM. *Bioinformatics (Oxford,*
1756 *England)*, 32(14), 2205–2207. <https://doi.org/10.1093/bioinformatics/btw203>
1757
1758 Grossman, S. R., Zhang, X., Wang, L., Engreitz, J., Melnikov, A., Rogov, P., Tewhey,
1759 R., Isakova, A., Deplancke, B., Bernstein, B. E., Mikkelsen, T. S., & Lander, E. S.
1760 (2017). Systematic dissection of genomic features determining transcription factor
1761 binding and enhancer function. *Proceedings of the National Academy of Sciences of the*
1762 *United States of America*, 114(7), E1291–E1300.
1763 <https://doi.org/10.1073/pnas.1621150114>
1764
1765 Grubert, F., Zaugg, J. B., Kasowski, M., Ursu, O., Spacek, D. V., Martin, A. R.,
1766 Greenside, P., Srivas, R., Phanstiel, D. H., Pekowska, A., Heidari, N., Euskirchen, G.,
1767 Huber, W., Pritchard, J. K., Bustamante, C. D., Steinmetz, L. M., Kundaje, A., & Snyder,
1768 M. (2015). Genetic Control of Chromatin States in Humans Involves Local and Distal
1769 Chromosomal Interactions. *Cell*, 162(5), 1051–1065.
1770 <https://doi.org/10.1016/j.cell.2015.07.048>
1771
1772 Guo, Y., Tian, K., Zeng, H., Guo, X., & Gifford, D. K. (2018). A novel *k*-mer set memory
1773 (KSM) motif representation improves regulatory variant prediction. *Genome*
1774 *Research*, 28(6), 891–900. <https://doi.org/10.1101/gr.226852.117>
1775
1776 Halow, J. M., Byron, R., Hogan, M. S., Ordoñez, R., Groudine, M., Bender, M. A.,
1777 Stamatoyannopoulos, J. A., & Maurano, M. T. (2021). Tissue context determines the
1778 penetrance of regulatory DNA variation. *Nature Communications*, 12(1), 2850.
1779 <https://doi.org/10.1038/s41467-021-23139-3>
1780
1781 He, X., Chatterjee, R., John, S., Bravo, H., Sathyanarayana, B. K., Biddie, S. C.,
1782 FitzGerald, P. C., Stamatoyannopoulos, J. A., Hager, G. L., & Vinson, C. (2013).
1783 Contribution of nucleosome binding preferences and co-occurring DNA sequences to
1784 transcription factor binding. *BMC Genomics*, 14, 428. [https://doi.org/10.1186/1471-](https://doi.org/10.1186/1471-2164-14-428)
1785 2164-14-428
1786
1787 He, L., Pratt, H., Gao, M., Wei, F., Weng, Z., & Struhl, K. (2021). YAP and TAZ are
1788 transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular
1789 transformation. *eLife*, 10, e67312. <https://doi.org/10.7554/eLife.67312>
1790
1791 Heintzman, N. D., Stuart, R. K., Hon, G., Fu, Y., Ching, C. W., Hawkins, R. D., Barrera, L. O.,
1792 Van Calcar, S., Qu, C., Ching, K. A., Wang, W., Weng, Z., Green, R. D., Crawford, G. E., &
1793 Ren, B. (2007). Distinct and predictive chromatin signatures of transcriptional promoters and
1794 enhancers in the human genome. *Nature Genetics*, 39(3), 311–318.
1795 <https://doi.org/10.1038/ng1966>

1796
1797 Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X.,
1798 Murre, C., Singh, H., & Glass, C. K. (2010). Simple combinations of lineage-determining
1799 transcription factors prime cis-regulatory elements required for macrophage and B cell
1800 identities. *Molecular Cell*, 38(4), 576–589. <https://doi.org/10.1016/j.molcel.2010.05.004>
1801
1802 Heinz, S., Romanoski, C. E., Benner, C., Allison, K. A., Kaikkonen, M. U., Orozco, L. D., &
1803 Glass, C. K. (2013). Effect of natural genetic variation on enhancer selection and
1804 function. *Nature*, 503(7477), 487–492. <https://doi.org/10.1038/nature12615>
1805
1806 Huang, S., Holt, J., Kao, C. Y., McMillan, L., & Wang, W. (2014). A novel multi-
1807 alignment pipeline for high-throughput sequencing data. *Database : The Journal of*
1808 *Biological Databases and Curation*, 2014, bau057.
1809 <https://doi.org/10.1093/database/bau057>
1810
1811 Jadhav, U., Cavazza, A., Banerjee, K. K., Xie, H., O'Neill, N. K., Saenz-Vash, V.,
1812 Herbert, Z., Madha, S., Orkin, S. H., Zhai, H., & Shivdasani, R. A. (2019). Extensive
1813 Recovery of Embryonic Enhancer and Gene Memory Stored in Hypomethylated
1814 Enhancer DNA. *Molecular Cell*, 74(3), 542–554.e5.
1815 <https://doi.org/10.1016/j.molcel.2019.02.024>
1816
1817 Jang, Y., Wang, C., Zhuang, L., Liu, C., & Ge, K. (2017). H3K4 Methyltransferase
1818 Activity Is Required for MLL4 Protein Stability. *Journal of Molecular Biology*, 429(13),
1819 2046–2054. <https://doi.org/10.1016/j.jmb.2016.12.016>
1820
1821 Jindal, G. A., & Farley, E. K. (2021). Enhancer grammar in development, evolution, and
1822 disease: dependencies and interplay. *Developmental Cell*, 56(5), 575–587.
1823 <https://doi.org/10.1016/j.devcel.2021.02.016>
1824
1825 Johnson, T. A., Chereji, R. V., Stavreva, D. A., Morris, S. A., Hager, G. L., & Clark, D. J.
1826 (2018). Conventional and pioneer modes of glucocorticoid receptor interaction with
1827 enhancer chromatin in vivo. *Nucleic Acids Research*, 46(1), 203–214.
1828 <https://doi.org/10.1093/nar/gkx1044>
1829
1830 Jolma, A., Yin, Y., Nitta, K. R., Dave, K., Popov, A., Taipale, M., Enge, M., Kivioja, T.,
1831 Morgunova, E., & Taipale, J. (2015). DNA-dependent formation of transcription factor
1832 pairs alters their binding specificity. *Nature*, 527(7578), 384–388.
1833 <https://doi.org/10.1038/nature15518>
1834
1835 Junion, G., Spivakov, M., Girardot, C., Braun, M., Gustafson, E. H., Birney, E., &
1836 Furlong, E. E. (2012). A transcription factor collective defines cardiac cell fate and
1837 reflects lineage history. *Cell*, 148(3), 473–486. <https://doi.org/10.1016/j.cell.2012.01.030>
1838
1839 Kaikkonen, M. U., Spann, N. J., Heinz, S., Romanoski, C. E., Allison, K. A., Stender, J. D.,
1840 Chun, H. B., Tough, D. F., Prinjha, R. K., Benner, C., & Glass, C. K. (2013). Remodeling of

1841 the enhancer landscape during macrophage activation is coupled to enhancer
1842 transcription. *Molecular Cell*, 51(3), 310–325. <https://doi.org/10.1016/j.molcel.2013.07.010>
1843
1844 Kasowski, M., Grubert, F., Heffelfinger, C., Hariharan, M., Asabere, A., Waszak, S. M.,
1845 Habegger, L., Rozowsky, J., Shi, M., Urban, A. E., Hong, M. Y., Karczewski, K. J.,
1846 Huber, W., Weissman, S. M., Gerstein, M. B., Korbel, J. O., & Snyder, M. (2010).
1847 Variation in transcription factor binding among humans. *Science (New York,*
1848 *N.Y.)*, 328(5975), 232–235. <https://doi.org/10.1126/science.1183621>
1849
1850 Keane, T. M., Goodstadt, L., Danecek, P., White, M. A., Wong, K., Yalcin, B., Heger, A.,
1851 Agam, A., Slater, G., Goodson, M., Furlotte, N. A., Eskin, E., Nellåker, C., Whitley, H., Cleak,
1852 J., Janowitz, D., Hernandez-Pliego, P., Edwards, A., Belgard, T. G., Oliver, P. L., ... Adams,
1853 D. J. (2011). Mouse genomic variation and its effect on phenotypes and gene
1854 regulation. *Nature*, 477(7364), 289–294. <https://doi.org/10.1038/nature10413>
1855
1856 Keilwagen, J., Posch, S., & Grau, J. (2019). Accurate prediction of cell type-specific
1857 transcription factor binding. *Genome Biology*, 20(1), 9. [https://doi.org/10.1186/s13059-](https://doi.org/10.1186/s13059-018-1614-y)
1858 [018-1614-y](https://doi.org/10.1186/s13059-018-1614-y)
1859
1860 Kilpinen, H., Waszak, S. M., Gschwind, A. R., Raghav, S. K., Witwicki, R. M., Orioli, A.,
1861 Migliavacca, E., Wiederkehr, M., Gutierrez-Arcelus, M., Panousis, N. I., Yurovsky, A.,
1862 Lappalainen, T., Romano-Palumbo, L., Planchon, A., Bielser, D., Bryois, J., Padioleau,
1863 I., Udin, G., Thurnheer, S., Hacker, D., ... Dermitzakis, E. T. (2013). Coordinated effects
1864 of sequence variation on DNA binding, chromatin structure, and transcription. *Science*
1865 *(New York, N.Y.)*, 342(6159), 744–747. <https://doi.org/10.1126/science.1242463>
1866
1867 Kim, T. H., Abdullaev, Z. K., Smith, A. D., Ching, K. A., Loukinov, D. I., Green, R. D.,
1868 Zhang, M. Q., Lobanenko, V. V., & Ren, B. (2007). Analysis of the vertebrate insulator
1869 protein CTCF-binding sites in the human genome. *Cell*, 128(6), 1231–1245.
1870 <https://doi.org/10.1016/j.cell.2006.12.048>
1871
1872 Kim, T. K., Hemberg, M., Gray, J. M., Costa, A. M., Bear, D. M., Wu, J., Harmin, D. A.,
1873 Laptewicz, M., Barbara-Haley, K., Kuersten, S., Markenscoff-Papadimitriou, E., Kuhl,
1874 D., Bito, H., Worley, P. F., Kreiman, G., & Greenberg, M. E. (2010). Widespread
1875 transcription at neuronal activity-regulated enhancers. *Nature*, 465(7295), 182–187.
1876 <https://doi.org/10.1038/nature09033>
1877
1878 Kim, T. K., & Shiekhhattar, R. (2015). Architectural and Functional Commonalities
1879 between Enhancers and Promoters. *Cell*, 162(5), 948–959.
1880 <https://doi.org/10.1016/j.cell.2015.08.008>
1881
1882 King, D. M., Hong, C., Shepherdson, J. L., Granas, D. M., Maricque, B. B., & Cohen, B.
1883 A. (2020). Synthetic and genomic regulatory elements reveal aspects of cis-regulatory
1884 grammar in mouse embryonic stem cells. *eLife*, 9, e41279.
1885 <https://doi.org/10.7554/eLife.41279>

1886
1887 Kharchenko, P. V., Tolstorukov, M. Y., & Park, P. J. (2008). Design and analysis of
1888 ChIP-seq experiments for DNA-binding proteins. *Nature Biotechnology*, *26*(12), 1351–
1889 1359. <https://doi.org/10.1038/nbt.1508>
1890
1891 Klein, J. C., Agarwal, V., Inoue, F., Keith, A., Martin, B., Kircher, M., Ahituv, N., &
1892 Shendure, J. (2020). A systematic evaluation of the design and context dependencies of
1893 massively parallel reporter assays. *Nature Methods*, *17*(11), 1083–1091.
1894 <https://doi.org/10.1038/s41592-020-0965-y>
1895
1896 Kribelbauer, J. F., Rastogi, C., Bussemaker, H. J., & Mann, R. S. (2019). Low-Affinity
1897 Binding Sites and the Transcription Factor Specificity Paradox in Eukaryotes. *Annual*
1898 *Review of Cell and Developmental Biology*, *35*, 357–379.
1899 <https://doi.org/10.1146/annurev-cellbio-100617-062719>
1900
1901 Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A.,
1902 Kheradpour, P., Zhang, Z., Wang, J., Ziller, M. J., Amin, V., Whitaker, J. W., Schultz, M.
1903 D., Ward, L. D., Sarkar, A., Quon, G., Sandstrom, R. S., Eaton, M. L., Wu, Y. C., ...
1904 Kellis, M. (2015). Integrative analysis of 111 reference human
1905 epigenomes. *Nature*, *518*(7539), 317–330. <https://doi.org/10.1038/nature14248>
1906
1907 Lappalainen T. (2015). Functional genomics bridges the gap between quantitative
1908 genetics and molecular biology. *Genome Research*, *25*(10), 1427–1431.
1909 <https://doi.org/10.1101/gr.190983.115>
1910
1911 Landt, S. G., Marinov, G. K., Kundaje, A., Kheradpour, P., Pauli, F., Batzoglou, S.,
1912 Bernstein, B. E., Bickel, P., Brown, J. B., Cayting, P., Chen, Y., DeSalvo, G., Epstein,
1913 C., Fisher-Aylor, K. I., Euskirchen, G., Gerstein, M., Gertz, J., Hartemink, A. J.,
1914 Hoffman, M. M., Iyer, V. R., ... Snyder, M. (2012). ChIP-seq guidelines and practices of
1915 the ENCODE and modENCODE consortia. *Genome Research*, *22*(9), 1813–1831.
1916 <https://doi.org/10.1101/gr.136184.111>
1917
1918 Langmead, B., & Salzberg, S. L. (2012). Fast gapped-read alignment with Bowtie
1919 2. *Nature Methods*, *9*(4), 357–359. <https://doi.org/10.1038/nmeth.1923>
1920
1921 Lappalainen, T., & MacArthur, D. G. (2021). From variant to function in human disease
1922 genetics. *Science (New York, N.Y.)*, *373*(6562), 1464–1468.
1923 <https://doi.org/10.1126/science.abi8207>
1924
1925 Lareau, C. A., & Aryee, M. J. (2018). hichipper: a preprocessing pipeline for calling DNA
1926 loops from HiChIP data. *Nature Methods*, *15*(3), 155–156.
1927 <https://doi.org/10.1038/nmeth.4583>
1928
1929 Leonard, D. A., & Kerppola, T. K. (1998). DNA bending determines Fos-Jun
1930 heterodimer orientation. *Nature Structural Biology*, *5*(10), 877–881.
1931 <https://doi.org/10.1038/2316>

1932
1933 Levo, M., & Segal, E. (2014). In pursuit of design principles of regulatory
1934 sequences. *Nature Reviews. Genetics*, 15(7), 453–468. <https://doi.org/10.1038/nrg3684>
1935
1936 Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G.,
1937 Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009).
1938 The Sequence Alignment/Map format and SAMtools. *Bioinformatics (Oxford,*
1939 *England)*, 25(16), 2078–2079. <https://doi.org/10.1093/bioinformatics/btp352>
1940
1941 Li, Q. V., Dixon, G., Verma, N., Rosen, B. P., Gordillo, M., Luo, R., Xu, C., Wang, Q.,
1942 Soh, C. L., Yang, D., Crespo, M., Shukla, A., Xiang, Q., Dündar, F., Zumbo, P., Witkin,
1943 M., Koche, R., Betel, D., Chen, S., Massagué, J., ... Huangfu, D. (2019). Genome-scale
1944 screens identify JNK-JUN signaling as a barrier for pluripotency exit and endoderm
1945 differentiation. *Nature Genetics*, 51(6), 999–1010. [https://doi.org/10.1038/s41588-019-](https://doi.org/10.1038/s41588-019-0408-9)
1946 [0408-9](https://doi.org/10.1038/s41588-019-0408-9)
1947
1948 Li, Y. I., van de Geijn, B., Raj, A., Knowles, D. A., Petti, A. A., Golan, D., Gilad, Y., &
1949 Pritchard, J. K. (2016). RNA splicing is a primary link between genetic variation and
1950 disease. *Science (New York, N.Y.)*, 352(6285), 600–604.
1951 <https://doi.org/10.1126/science.aad9417>
1952
1953 Lidor Nili, E., Field, Y., Lubling, Y., Widom, J., Oren, M., & Segal, E. (2010). p53 binds
1954 preferentially to genomic regions with high DNA-encoded nucleosome
1955 occupancy. *Genome Research*, 20(10), 1361–1368.
1956 <https://doi.org/10.1101/gr.103945.109>
1957
1958 Liu T. (2014). Use model-based Analysis of ChIP-Seq (MACS) to analyze short reads
1959 generated by sequencing protein-DNA interactions in embryonic stem cells. *Methods in*
1960 *Molecular Biology (Clifton, N.J.)*, 1150, 81–95. [https://doi.org/10.1007/978-1-4939-0512-](https://doi.org/10.1007/978-1-4939-0512-6_4)
1961 [6_4](https://doi.org/10.1007/978-1-4939-0512-6_4)
1962
1963 Liu, X., Li, H., Rajurkar, M., Li, Q., Cotton, J. L., Ou, J., Zhu, L. J., Goel, H. L., Mercurio,
1964 A. M., Park, J. S., Davis, R. J., & Mao, J. (2016). Tead and AP1 Coordinate
1965 Transcription and Motility. *Cell Reports*, 14(5), 1169–1180.
1966 <https://doi.org/10.1016/j.celrep.2015.12.104>
1967
1968 Liao, Y., Smyth, G. K., & Shi, W. (2013). The Subread aligner: fast, accurate and
1969 scalable read mapping by seed-and-vote. *Nucleic Acids Research*, 41(10), e108.
1970 <https://doi.org/10.1093/nar/gkt214>
1971
1972 Link, V. M., Duttke, S. H., Chun, H. B., Holtman, I. R., Westin, E., Hoeksema, M. A., Abe,
1973 Y., Skola, D., Romanoski, C. E., Tao, J., Fonseca, G. J., Troutman, T. D., Spann, N. J., Strid, T.,
1974 Sakai, M., Yu, M., Hu, R., Fang, R., Metzler, D., Ren, B., ... Glass, C. K. (2018). Analysis of
1975 Genetically Diverse Macrophages Reveals Local and Domain-wide Mechanisms that Control
1976 Transcription Factor Binding and Function. *Cell*, 173(7), 1796–1809.e17.
1977 <https://doi.org/10.1016/j.cell.2018.04.018>

1978
1979 Long, H. K., Prescott, S. L., & Wysocka, J. (2016). Ever-Changing Landscapes: Transcriptional
1980 Enhancers in Development and Evolution. *Cell*, *167*(5), 1170–1187.
1981 <https://doi.org/10.1016/j.cell.2016.09.018>
1982
1983 Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and
1984 dispersion for RNA-seq data with DESeq2. *Genome Biology*, *15*(12), 550.
1985 <https://doi.org/10.1186/s13059-014-0550-8>
1986
1987 Malik, A. N., Vierbuchen, T., Hemberg, M., Rubin, A. A., Ling, E., Couch, C. H., Stroud, H.,
1988 Spiegel, I., Farh, K. K., Harmin, D. A., & Greenberg, M. E. (2014). Genome-wide
1989 identification and characterization of functional neuronal activity-dependent
1990 enhancers. *Nature Neuroscience*, *17*(10), 1330–1339. <https://doi.org/10.1038/nn.3808>
1991
1992 Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds,
1993 A. P., Sandstrom, R., Qu, H., Brody, J., Shafer, A., Neri, F., Lee, K., Kuttyavin, T., Stehling-
1994 Sun, S., Johnson, A. K., Canfield, T. K., Giste, E., Diegel, M., Bates, D., ...
1995 Stamatoyannopoulos, J. A. (2012). Systematic localization of common disease-associated
1996 variation in regulatory DNA. *Science (New York, N.Y.)*, *337*(6099), 1190–1195.
1997 <https://doi.org/10.1126/science.1222794>
1998
1999 Maurano, M. T., Haugen, E., Sandstrom, R., Vierstra, J., Shafer, A., Kaul, R., &
2000 Stamatoyannopoulos, J. A. (2015). Large-scale identification of sequence variants influencing
2001 human transcription factor occupancy in vivo. *Nature Genetics*, *47*(12), 1393–1401.
2002 <https://doi.org/10.1038/ng.3432>
2003
2004 Meuleman, W., Muratov, A., Rynes, E., Halow, J., Lee, K., Bates, D., Diegel, M., Dunn, D.,
2005 Neri, F., Teodosiadis, A., Reynolds, A., Haugen, E., Nelson, J., Johnson, A., Frerker, M.,
2006 Buckley, M., Sandstrom, R., Vierstra, J., Kaul, R., & Stamatoyannopoulos, J. (2020). Index and
2007 biological spectrum of human DNase I hypersensitive sites. *Nature*, *584*(7820), 244–251.
2008 <https://doi.org/10.1038/s41586-020-2559-3>
2009
2010 Michael, A. K., & Thomä, N. H. (2021). Reading the chromatinized
2011 genome. *Cell*, *184*(14), 3599–3611. <https://doi.org/10.1016/j.cell.2021.05.029>
2012
2013 Miller, J. A., & Widom, J. (2003). Collaborative competition mechanism for gene activation
2014 in vivo. *Molecular and Cellular Biology*, *23*(5), 1623–1632.
2015 <https://doi.org/10.1128/MCB.23.5.1623-1632.2003>
2016

2017 Moyle-Heyrman, G., Tims, H. S., & Widom, J. (2011). Structural constraints in collaborative
2018 competition of transcription factors against the nucleosome. *Journal of Molecular*
2019 *Biology*, 412(4), 634–646. <https://doi.org/10.1016/j.jmb.2011.07.032>
2020

2021 Mumbach, M. R., Satpathy, A. T., Boyle, E. A., Dai, C., Gowen, B. G., Cho, S. W., Nguyen,
2022 M. L., Rubin, A. J., Granja, J. M., Kazane, K. R., Wei, Y., Nguyen, T., Greenside, P. G.,
2023 Corces, M. R., Tycko, J., Simeonov, D. R., Suliman, N., Li, R., Xu, J., Flynn, R. A., ... Chang,
2024 H. Y. (2017). Enhancer connectome in primary human cells identifies target genes of disease-
2025 associated DNA elements. *Nature Genetics*, 49(11), 1602–1612.
2026 <https://doi.org/10.1038/ng.3963>
2027

2028 Nasser, J., Bergman, D. T., Fulco, C. P., Guckelberger, P., Doughty, B. R., Patwardhan, T. A.,
2029 Jones, T. R., Nguyen, T. H., Ulirsch, J. C., Lekschas, F., Mualim, K., Natri, H. M., Weeks, E.
2030 M., Munson, G., Kane, M., Kang, H. Y., Cui, A., Ray, J. P., Eisenhaure, T. M., Collins, R. L.,
2031 ... Engreitz, J. M. (2021). Genome-wide enhancer maps link risk variants to disease
2032 genes. *Nature*, 593(7858), 238–243. <https://doi.org/10.1038/s41586-021-03446-x>
2033

2034 Osterwalder, M., Barozzi, I., Tissières, V., Fukuda-Yuzawa, Y., Mannion, B. J., Afzal, S. Y.,
2035 Lee, E. A., Zhu, Y., Plajzer-Frick, I., Pickle, C. S., Kato, M., Garvin, T. H., Pham, Q. T.,
2036 Harrington, A. N., Akiyama, J. A., Afzal, V., Lopez-Rios, J., Dickel, D. E., Visel, A., &
2037 Pennacchio, L. A. (2018). Enhancer redundancy provides phenotypic robustness in
2038 mammalian development. *Nature*, 554(7691), 239–243. <https://doi.org/10.1038/nature25461>
2039

2040 Ou, S., Su, W., Liao, Y., Chougule, K., Agda, J., Hellinga, A. J., Lugo, C., Elliott, T. A., Ware,
2041 D., Peterson, T., Jiang, N., Hirsch, C. N., & Hufford, M. B. (2019). Benchmarking
2042 transposable element annotation methods for creation of a streamlined, comprehensive
2043 pipeline. *Genome Biology*, 20(1), 275. <https://doi.org/10.1186/s13059-019-1905-y>
2044

2045 Quinlan, A. R., & Hall, I. M. (2010). BEDTools: a flexible suite of utilities for comparing
2046 genomic features. *Bioinformatics (Oxford, England)*, 26(6), 841–842.
2047 <https://doi.org/10.1093/bioinformatics/btq033>
2048

2049 Paakinaho, V., Presman, D. M., Ball, D. A., Johnson, T. A., Schiltz, R. L., Levitt, P., Mazza,
2050 D., Morisaki, T., Karpova, T. S., & Hager, G. L. (2017). Single-molecule analysis of steroid
2051 receptor and cofactor action in living cells. *Nature Communications*, 8, 15896.
2052 <https://doi.org/10.1038/ncomms15896>
2053

2054 Pai, A. A., Pritchard, J. K., & Gilad, Y. (2015). The genetic and mechanistic basis for
2055 variation in gene regulation. *PLoS Genetics*, 11(1), e1004857.
2056 <https://doi.org/10.1371/journal.pgen.1004857>
2057

2058 Park, J., Eisenbarth, D., Choi, W., Kim, H., Choi, C., Lee, D., & Lim, D. S. (2020). YAP
2059 and AP-1 Cooperate to Initiate Pancreatic Cancer Development from Ductal Cells in
2060 Mice. *Cancer Research*, *80*(21), 4768–4779. [https://doi.org/10.1158/0008-5472.CAN-](https://doi.org/10.1158/0008-5472.CAN-20-0907)
2061 [20-0907](https://doi.org/10.1158/0008-5472.CAN-20-0907)
2062
2063 Pickrell J. K. (2014). Joint analysis of functional genomic data and genome-wide
2064 association studies of 18 human traits. *American Journal of Human Genetics*, *94*(4),
2065 559–573. <https://doi.org/10.1016/j.ajhg.2014.03.004>
2066
2067 Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S. A., Flynn, R. A., & Wysocka, J. (2011).
2068 A unique chromatin signature uncovers early developmental enhancers in
2069 humans. *Nature*, *470*(7333), 279–283. <https://doi.org/10.1038/nature09692>
2070
2071 Rickels, R., Herz, H. M., Sze, C. C., Cao, K., Morgan, M. A., Collings, C. K., Gause, M.,
2072 Takahashi, Y. H., Wang, L., Rendleman, E. J., Marshall, S. A., Krueger, A., Bartom, E. T.,
2073 Piunti, A., Smith, E. R., Abshiru, N. A., Kelleher, N. L., Dorsett, D., & Shilatifard, A. (2017).
2074 Histone H3K4 monomethylation catalyzed by Trr and mammalian COMPASS-like proteins
2075 at enhancers is dispensable for development and viability. *Nature Genetics*, *49*(11), 1647–
2076 1653. <https://doi.org/10.1038/ng.3965>
2077
2078 Risse, G., Jooss, K., Neuberg, M., Brüller, H. J., & Müller, R. (1989). Asymmetrical
2079 recognition of the palindromic AP1 binding site (TRE) by Fos protein complexes. *The EMBO*
2080 *Journal*, *8*(12), 3825–3832.
2081
2082 Roberts, G. A., Ozkan, B., Gachulinová, I., O'Dwyer, M. R., Hall-Ponsele, E., Saxena, M.,
2083 Robinson, P. J., & Soufi, A. (2021). Dissecting OCT4 defines the role of nucleosome binding
2084 in pluripotency. *Nature Cell Biology*, *23*(8), 834–845. [https://doi.org/10.1038/s41556-021-](https://doi.org/10.1038/s41556-021-00727-5)
2085 [00727-5](https://doi.org/10.1038/s41556-021-00727-5)
2086
2087 Rohs, R., Jin, X., West, S. M., Joshi, R., Honig, B., & Mann, R. S. (2010). Origins of specificity
2088 in protein-DNA recognition. *Annual Review of Biochemistry*, *79*, 233–269.
2089 <https://doi.org/10.1146/annurev-biochem-060408-091030>
2090
2091 Schmidt, D., Schwalie, P. C., Wilson, M. D., Ballester, B., Gonçalves, A., Kutter, C., Brown,
2092 G. D., Marshall, A., Flicek, P., & Odom, D. T. (2012). Waves of retrotransposon expansion
2093 remodel genome organization and CTCF binding in multiple mammalian
2094 lineages. *Cell*, *148*(1-2), 335–348. <https://doi.org/10.1016/j.cell.2011.11.058>
2095
2096 Seo, J., Koçak, D. D., Bartelt, L. C., Williams, C. A., Barrera, A., Gersbach, C. A., & Reddy, T.
2097 E. (2021). AP-1 subunits converge promiscuously at enhancers to potentiate
2098 transcription. *Genome Research*, *31*(4), 538–550. <https://doi.org/10.1101/gr.267898.120>
2099

2100 Servant, N., Varoquaux, N., Lajoie, B. R., Viara, E., Chen, C. J., Vert, J. P., Heard, E., Dekker,
2101 J., & Barillot, E. (2015). HiC-Pro: an optimized and flexible pipeline for Hi-C data
2102 processing. *Genome Biology*, *16*, 259. <https://doi.org/10.1186/s13059-015-0831-x>
2103

2104 Sharma, N., Pollina, E. A., Nagy, M. A., Yap, E. L., DiBiase, F. A., Hrvatin, S., Hu, L., Lin, C.,
2105 & Greenberg, M. E. (2019). ARNT2 Tunes Activity-Dependent Gene Expression through
2106 NCoR2-Mediated Repression and NPAS4-Mediated Activation. *Neuron*, *102*(2), 390–406.e9.
2107 <https://doi.org/10.1016/j.neuron.2019.02.007>
2108

2109 Shen, S. Q., Turro, E., & Corbo, J. C. (2014). Hybrid mice reveal parent-of-origin and Cis-
2110 and trans-regulatory effects in the retina. *PLoS One*, *9*(10), e109382.
2111 <https://doi.org/10.1371/journal.pone.0109382>
2112

2113 Shen, Z., Li, R. Z., Prohaska, T. A., Hoeksema, M. A., Spann, N. J., Tao, J., Fonseca, G. J., Le,
2114 T., Stolze, L., Sakai, M., Romanoski, C. E., & Glass, C. K. (2021). Systematic analysis of
2115 naturally occurring insertions and deletions that alter transcription factor spacing identifies
2116 tolerant and sensitive transcription factor pairs. *bioRxiv* 2020.04.02.021535; doi:
2117 <https://doi.org/10.1101/2020.04.02.021535>
2118

2119 Skene, P. J., & Henikoff, S. (2017). An efficient targeted nuclease strategy for high-resolution
2120 mapping of DNA binding sites. *eLife*, *6*, e21856. <https://doi.org/10.7554/eLife.21856>
2121

2122 Soufi, A., Garcia, M. F., Jaroszewicz, A., Osman, N., Pellegrini, M., & Zaret, K. S. (2015).
2123 Pioneer transcription factors target partial DNA motifs on nucleosomes to initiate
2124 reprogramming. *Cell*, *161*(3), 555–568. <https://doi.org/10.1016/j.cell.2015.03.017>
2125

2126 Spitz, F., & Furlong, E. E. (2012). Transcription factors: from enhancer binding to
2127 developmental control. *Nature Reviews. Genetics*, *13*(9), 613–626.
2128 <https://doi.org/10.1038/nrg3207>
2129

2130 Sun W. (2012). A statistical framework for eQTL mapping using RNA-seq
2131 data. *Biometrics*, *68*(1), 1–11. <https://doi.org/10.1111/j.1541-0420.2011.01654.x>
2132

2133 Tehranchi, A. K., Myrthil, M., Martin, T., Hie, B. L., Golan, D., & Fraser, H. B. (2016). Pooled
2134 ChIP-Seq Links Variation in Transcription Factor Binding to Complex Disease
2135 Risk. *Cell*, *165*(3), 730–741. <https://doi.org/10.1016/j.cell.2016.03.041>
2136

2137 Tillo, D., Kaplan, N., Moore, I. K., Fondufe-Mittendorf, Y., Gossett, A. J., Field, Y., Lieb, J. D.,
2138 Widom, J., Segal, E., & Hughes, T. R. (2010). High nucleosome occupancy is encoded at
2139 human regulatory sequences. *PLoS One*, *5*(2), e9129.
2140 <https://doi.org/10.1371/journal.pone.0009129>

2141
2142 van de Geijn, B., McVicker, G., Gilad, Y., & Pritchard, J. K. (2015). WASP: allele-specific
2143 software for robust molecular quantitative trait locus discovery. *Nature Methods*, *12*(11),
2144 1061–1063. <https://doi.org/10.1038/nmeth.3582>
2145
2146 van der Veecken, J., Zhong, Y., Sharma, R., Mazutis, L., Dao, P., Pe'er, D., Leslie, C. S., &
2147 Rudensky, A. Y. (2019). Natural Genetic Variation Reveals Key Features of Epigenetic and
2148 Transcriptional Memory in Virus-Specific CD8 T Cells. *Immunity*, *50*(5), 1202–1217.e7.
2149 <https://doi.org/10.1016/j.immuni.2019.03.031>
2150
2151 VandenBosch, L. S., Luu, K., Timms, A. E., Challam, S., Wu, Y., Lee, A. Y., & Cherry, T. J.
2152 (2022). Machine Learning Prediction of Non-Coding Variant Impact in Human Retinal cis-
2153 Regulatory Elements. *Translational vision science & technology*, *11*(4), 16.
2154 <https://doi.org/10.1167/tvst.11.4.16>
2155
2156 Vierbuchen, T., Ling, E., Cowley, C. J., Couch, C. H., Wang, X., Harmin, D. A., Roberts, C.,
2157 & Greenberg, M. E. (2017). AP-1 Transcription Factors and the BAF Complex Mediate
2158 Signal-Dependent Enhancer Selection. *Molecular Cell*, *68*(6), 1067–1082.e12.
2159 <https://doi.org/10.1016/j.molcel.2017.11.026>
2160
2161 Vierstra, J., Lazar, J., Sandstrom, R., Halow, J., Lee, K., Bates, D., Diegel, M., Dunn, D., Neri,
2162 F., Haugen, E., Rynes, E., Reynolds, A., Nelson, J., Johnson, A., Frerker, M., Buckley, M.,
2163 Kaul, R., Meuleman, W., & Stamatoyannopoulos, J. A. (2020). Global reference mapping of
2164 human transcription factor footprints. *Nature*, *583*(7818), 729–736.
2165 <https://doi.org/10.1038/s41586-020-2528-x>
2166
2167 Villar, D., Berthelot, C., Aldridge, S., Rayner, T. F., Lukk, M., Pignatelli, M., Park, T. J.,
2168 Deaville, R., Erichsen, J. T., Jasinska, A. J., Turner, J. M., Bertelsen, M. F., Murchison, E. P.,
2169 Flicek, P., & Odom, D. T. (2015). Enhancer evolution across 20 mammalian
2170 species. *Cell*, *160*(3), 554–566. <https://doi.org/10.1016/j.cell.2015.01.006>
2171
2172 Wei, B., Jolma, A., Sahu, B., Orre, L. M., Zhong, F., Zhu, F., Kivioja, T., Sur, I., Lehtiö, J.,
2173 Taipale, M., & Taipale, J. (2018). A protein activity assay to measure global transcription
2174 factor activity reveals determinants of chromatin accessibility. *Nature Biotechnology*, *36*(6),
2175 521–529. <https://doi.org/10.1038/nbt.4138>
2176
2177 Wittkopp, P. J., & Kalay, G. (2011). Cis-regulatory elements: molecular mechanisms and
2178 evolutionary processes underlying divergence. *Nature Reviews. Genetics*, *13*(1), 59–69.
2179 <https://doi.org/10.1038/nrg3095>
2180

2181 Wong, E. S., Schmitt, B. M., Kazachenka, A., Thybert, D., Redmond, A., Connor, F., Rayner,
2182 T. F., Feig, C., Ferguson-Smith, A. C., Marioni, J. C., Odom, D. T., & Flicek, P. (2017).
2183 Interplay of cis and trans mechanisms driving transcription factor binding and gene
2184 expression evolution. *Nature Communications*, *8*(1), 1092. [https://doi.org/10.1038/s41467-](https://doi.org/10.1038/s41467-017-01037-x)
2185 [017-01037-x](https://doi.org/10.1038/s41467-017-01037-x)
2186
2187 Yella, V. R., Bhimsaria, D., Ghoshdastidar, D., Rodríguez-Martínez, J. A., Ansari, A. Z., &
2188 Bansal, M. (2018). Flexibility and structure of flanking DNA impact transcription factor
2189 affinity for its core motif. *Nucleic Acids Research*, *46*(22), 11883–11897.
2190 <https://doi.org/10.1093/nar/gky1057>
2191
2192 Zanconato, F., Forcato, M., Battilana, G., Azzolin, L., Quaranta, E., Bodega, B., Rosato, A.,
2193 Biciato, S., Cordenonsi, M., & Piccolo, S. (2015). Genome-wide association between
2194 YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. *Nature Cell*
2195 *Biology*, *17*(9), 1218–1227. <https://doi.org/10.1038/ncb3216>
2196
2197 Zeitlinger J. (2020). Seven myths of how transcription factors read the cis-regulatory
2198 code. *Current Opinion in Systems Biology*, *23*, 22–31.
2199 <https://doi.org/10.1016/j.coisb.2020.08.002>
2200
2201 Zhou, K., Gaullier, G., & Luger, K. (2019). Nucleosome structure and dynamics are coming of
2202 age. *Nature Structural & Molecular Biology*, *26*(1), 3–13. [https://doi.org/10.1038/s41594-018-](https://doi.org/10.1038/s41594-018-0166-x)
2203 [0166-x](https://doi.org/10.1038/s41594-018-0166-x)
2204
2205 Zhu, F., Farnung, L., Kaasinen, E., Sahu, B., Yin, Y., Wei, B., Dodonova, S. O., Nitta, K. R.,
2206 Morgunova, E., Taipale, M., Cramer, P., & Taipale, J. (2018). The interaction landscape
2207 between transcription factors and the nucleosome. *Nature*, *562*(7725), 76–81.
2208 <https://doi.org/10.1038/s41586-018-0549-5>
2209
2210 Zhu, Q., Liu, N., Orkin, S. H., & Yuan, G. C. (2019). CUT&RUNTools: a flexible pipeline for
2211 CUT&RUN processing and footprint analysis. *Genome Biology*, *20*(1), 192.
2212 <https://doi.org/10.1186/s13059-019-1802-4>
2213




Figure 1. Allele-specific mapping of CREs and TF binding.




Figure 1 -- figure supplement 1. Identification of allele-specific transcripts using chromatin-associated RNA-seq.




Figure 3. Sequence motifs and changes in chromatin state at allele-specific TF-bound sites.




Figure 1 -- figure supplement 2. Properties of allele-specific enhancers and association with gene expression.




Figure 2. Number and position of sequence variants at allele-specific CREs.




Figure 2 -- figure supplement 1. Contribution of locus-scale, *cis*-acting mechanisms to enhancer activity.




Figure 2 -- figure supplement 2. Quantification of *trans*-acting effects on enhancer chromatin state and gene expression.




Figure 3. Sequence motifs and changes in chromatin state at allele-specific TF-bound sites.




Figure 3 -- figure supplement 1. Sequence determinants of AP-1 binding.




Figure 3 -- figure supplement 2. Comparison of ChIP-seq and CUT&RUN datasets.




Figure 4. Mechanisms of hierarchical binding for AP-1 and TEAD TFs.




Figure 5. Distribution of sequence variants that influence AP-1, TEAD, and CTCF binding




Figure 6. Machine learning prediction of AP-1 binding sites genome-wide.




Figure 6 -- figure supplement 1. Application of the gkm-svm algorithm identifies k-mers required for AP-1, TEAD, and CTCF binding